Combining machine learning and mathematical models of disease dynamics to 1

2

guide development of novel disease interventions

3 4

5

6

Authors: Monica Golumbeanu^{1,2}[†], Guojing Yang^{1,2}[†], Flavia Camponovo^{1,2,3}, Erin M. Stuckey⁴, Nicholas Hamon⁵, Mathias Mondy⁵, Sarah Rees⁵, Nakul Chitnis^{1,2}, Ewan Cameron^{6,7,8}, and

Melissa A. Pennv^{1,2}*

7 **Affiliations:**

- ¹Swiss Tropical and Public Health Institute, Basel, Switzerland 8
- 9 ²University of Basel, Basel, Switzerland
- ³Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. 10
- Chan School of Public Health, Boston, MA 02115, USA 11
- ⁴The Bill and Melinda Gates Foundation, Seattle, WA, USA 12
- ⁵Innovative Vector Control Consortium, Liverpool, United Kingdom 13
- ⁶Malaria Atlas Project, Big Data Institute, University of Oxford, Oxford, UK 14
- ⁷Curtin University, Perth, Australia 15
- ⁸Telethon Kids Institute, Perth Children's Hospital, Perth, Australia 16
- [†]These authors contributed equally. 17
- **Email:** *Correspondence to: melissa.penny@unibas.ch 18
- 19

One Sentence Summary: Defining quantitative profiles of novel disease interventions by 20

- combining machine learning with mathematical models of disease transmission 21
- 22 Abstract:

The development of novel interventions against a disease entails optimising their specifications 23 to achieve desired health goals such as disease reduction. As testing is limited early in 24 development, it is difficult to predefine these optimal specifications, prioritize or continue 25 26 investment in candidate interventions. Mathematical models of disease can provide quantitative evidence as they can simulate deployment and predict impact of a new intervention considering 27 28 deployment, health-system, population and disease characteristics. However, due to large 29 uncertainty early in development, as well as model complexity, testing all possible combinations 30 of interventions and deployments becomes infeasible. As a result, mathematical models have been only marginally used during intervention development to date. Here, we present a new 31 32 approach where machine learning enables the use of detailed disease models to identify optimal properties of candidate interventions to reach a desired health goal and guide development. We 33 demonstrate the power of our approach by application to five novel malaria interventions under 34 development. For various targeted reductions of malaria prevalence, we quantify and rank 35 intervention characteristics which are key determinants of health impact. Furthermore, we 36 identify minimal requirements and tradeoffs between operational factors, intervention efficacy 37 and duration to achieve different levels of impact and show how these vary across disease 38 transmission settings. When single interventions cannot achieve significant impact, our method 39 allows finding optimal combinations of interventions fulfilling the desired health goals. By 40 enabling efficient use of disease models, our approach supports decision-making and resource 41 investment in the development of new interventions for infectious diseases. 42

44 Significance Statement

During development of novel disease interventions (e.g. vaccines), a target product profile (TPP) 45 document defines intervention characteristics required to meet health goals. As clinical trials are 46 47 limited early in development, mathematical models simulating disease dynamics can help define TPPs. However, testing all combinations of intervention, delivery and environment 48 characteristics is infeasible and so complex mathematical models have not been used until now. 49 We introduce a new approach to define TPPs, combining models of disease with machine 50 learning. We examined several novel malaria interventions, identifying key characteristics, 51 minimum efficacy and duration of effect that ensure significant reductions in malaria prevalence. 52 53 This approach therefore enabled mathematical models of disease to support intervention development, by identifying intervention requirements that ensure public health impact. 54

55 Introduction

Target Product Profiles (TPPs) are dynamic documents commonly used during the development 56 of a cutting-edge medical product, defining its required characteristics to fulfill an unmet health 57 58 need (1). By offering a comprehensive snapshot of the development process at any given point in time, a TPP constitutes a vital reference for dialogue between various stakeholders to guide 59 decisions on the development direction to be pursued (1-5). A well-constructed TPP is thus 60 essential for efficient resource allocation and success during the development phase (1, 5). 61 62 However, the process of establishing TPPs relies on minimal clinical or quantitative evidence. They are often set by expert opinion and consensus based on limited quantitative consideration 63 64 of the complex dynamics of disease or predictions of the likely intervention impact while achieving the identified unmet health need (6). Furthermore, few TPPs consider operational 65 aspects such as deployment coverage in addition to product-specific characteristics such as 66 efficacy or half-life. This has implications for the appropriate definition of intervention 67 effectiveness characteristics according to local health systems and health targets (1, 6, 7). 68

Mathematical models of disease transmission dynamics can be used to bridge this gap, as they 69 quantitatively estimate the impact of interventions while including considerable evidence of 70 disease progression and transmission, host immunity, as well as environmental or health system 71 dynamics and their interaction with interventions (8, 9) (Fig. 1). However, models have been 72 mainly used at late stages during the development of a new intervention; for example, to predict 73 likely impact or cost-effectiveness from data collected in Phase 3 clinical trials (10-15). Model 74 investigations are usually informed by scenario analysis accounting for the delivery and target 75 age groups, as well as properties of the new intervention pre-defined or informed by late clinical 76 trials (16-19). In these constrained scenarios, high model and parameter complexity tend to 77 obscure the complex relationships between intervention parameters, operational factors, health 78 outcomes and public health impact (20). Exhaustive scenario analyses are highly 79 80 computationally expensive, rendering the full exploration of all possible interventions for a disease, in conjunction with all possible delivery scenarios, combinatorically infeasible. 81

Here we propose a new ethos where epidemiological models guide the development of novel
disease interventions designed to achieve quantified health goals. To do this efficiently, we use

machine learning combined with mathematical models to perform a directed search of the entire 84 space of intervention profiles, to define properties of new interventions (sometimes referred to as 85 "tools" or "products") that will achieve the desired health goal. Placing the end goal of public 86 health impact at the center of decision making is increasingly important to direct Research & 87 Development (R&D) efforts in the face of finite resources. The use of mathematical models 88 enables translation of R&D efforts into potential impact. In this paper, we show how modelling 89 can support this process, and introduce a framework that quantitatively defines product 90 characteristics within TPPs. 91

Previous approaches using disease models to inform TPPs have tackled the combinatorically-92 93 complex parameter space by only exploring a discrete, constrained set of parameters (21-23). These approaches have provided insightful knowledge and emphasized the importance of using 94 95 disease models for defining TPPs. Nevertheless, they have provided a concomitantly constrained view of intervention specifications. Our framework tackles and moves beyond these challenges. 96 97 On one hand, it allows us to rigorously define TPPs by efficiently exploring highly complex parameter spaces of mathematical disease models, and on the other hand it identifies the 98 99 determinants of desired public health impact to inform tradeoffs between product characteristics and use-cases. Furthermore, as the ultimate health goal guides decisions on interventions and for 100 optimal use of the supportive framework presented here, an engaging, iterative exchange with 101 stakeholders to define desired outcomes and the likely delivery use-cases of the new 102 103 interventions is essential.

Our framework utilizes a machine learning approach using Gaussian processes (GPs) (24) to 104 generate computationally light emulators of detailed mathematical models of disease dynamics 105 (Fig. 2A). These emulators constitute an interface that easily links properties of deployed 106 interventions and operational factors to health goals. Furthermore, the emulators capture not just 107 the mean tendency of complex disease models dynamics, but also the inherent variance caused 108 109 by the stochasticity in the models (25). Disease model emulators allowed us to efficiently 110 perform sensitivity analyses of intervention and health system parameters on predicted public health impacts at low computational cost. Furthermore, by coupling emulators with nonlinear 111 optimization techniques, we constructed a predictive framework that identifies key determinants 112 113 of intervention impact as well as the minimal intervention profiles required for achieving a given

health goal (Fig. 2). The framework consists of (i) a comprehensive disease progression and 114 transmission simulation model applied on a discrete, uniformly sampled set of input parameters; 115 116 (ii) training of an emulator on the sampled set of parameters and corresponding impact outcomes; (iii) using sensitivity analysis to understand drivers of intervention impact; and (iv) 117 applying a non-linear constrained optimization algorithm to explore intervention operational and 118 effectiveness characteristics meeting various targets and deployment use-cases specified 119 following iterative consultation with product development experts. A detailed description of the 120 components of the developed framework can be found in Fig. 2A and the Materials and Methods 121

section.

123 We apply our framework to assess and optimize new interventions for preventing malaria

124 transmission. Strategic investment in new interventions is becoming crucial for malaria control

125 and elimination programs, as existing interventions are currently challenged by increasing

resistance (26-28). Mathematical models of malaria transmission (Fig. 1) have been used

127 extensively to estimate the impact of malaria interventions and to optimize intervention packages

128 for specific geographies (10, 29-32). As yet, these malaria models have not been systematically

applied in directing the design of new interventions, nor in understanding how intervention-

130 specific, epidemiological and systems factors jointly contribute to impact. Following


131 consultation with malaria product development experts, we used our new framework to define

132 the required profiles in terms of coverage, efficacy and duration characteristics in TPPs of new


133 putative malaria interventions to reach desired public health goals such as prevalence reduction

134 contingent on operational constraints (Fig. 2).

135







154 **Results**


155 A disease model and machine learning approach to quantitatively define malaria interventions

Our analysis workflow (Fig. 2) starts with sensibly-informed TPP scenarios; the definition of 156 targeted health goals corresponding to unmet health needs; and possible use cases following 157 158 continuous consultation with product development experts. The health goals in the present analysis are reductions of malaria prevalence for all ages ($PfPR_{0.99}$) and prevention of 159 resurgence. Next, within the "Disease model" component, malaria transmission is modeled by 160 the means of the established, stochastic, individual-based model OpenMalaria (33) (Fig. 1, Table 161 162 S1.1). A comprehensive set of simulated scenarios is built by uniformly sampling the parameter space (defined by the parameters emphasized in bold under "Tool specifications" and "Setting" 163 components in Fig. 2 and detailed in Table S2.1). The scenarios are simulated with the disease 164 model yielding an extensive database of disease outcomes. In the machine learning part of the 165 approach, the database of simulated scenarios and corresponding outcomes is used to train a 166 predictive model, in this case a Heteroskedastic Gaussian process model (see detailed training 167 procedure in Materials and Methods). The predictive model acts as an emulator of the complex 168 individual-based mathematical model. Specifically, the emulator can predict the disease outcome 169 for the given health goal and any set of input parameters. For this reason, the trained emulator 170 can be efficiently and promptly used in downstream analyses to design TPPs of new malaria 171 interventions, and to identify their quantitative properties to meet the health goal previously 172 defined. More precisely, sensitivity analysis allows searching for key determinants of 173 intervention impact, while constrained optimization analyses yield the optimal required 174 intervention properties that meet specified impactful health goals. 175

We used our validated individual-based model, "OpenMalaria" (29, 33) (detailed description in 176 the Materials and Methods section, Fig. 1 and Table S1.1) to simulate malaria epidemiology and 177 transmission dynamics within various transmission settings. These settings cover a broad 178 179 spectrum of transmission and mosquito biting behavior archetypes relevant for attaining general 180 guiding principles in the early development phase of new interventions. Within the simulations, we quantitatively examined several malaria interventions that are currently under development or 181 developed within the last ten years, including monoclonal antibodies, drugs, vaccines as well as 182 183 novel vector control interventions. To be able to investigate a wide range of interventions,

instead of considering their characteristics explicitly, we more generally modelled their action on
parasite or vector targets (Fig. 1). Accordingly, each intervention was modeled through its
deployment coverage, efficacy, half-life or duration of effect on the given parasite or vector stage
in the transmission cycle (see Materials and Methods, Fig. S2.3, Table S2.1 for detailed
intervention specifications). For simplification, the words 'half-life and 'duration' are used
interchangeably to describe the longevity of the intervention effect (further details and
definitions in Materials and Methods).

191 Intervention impact in the current study was assessed assuming a single health goal of malaria prevalence reduction and thus through predicted reduction in *Plasmodium falciparum* malaria 192 prevalence across all ages, $P_f PR_{0.99}$, corresponding to true infection prevalence and not patent 193 (detected with a diagnostic such as rapid diagnostic test (RDT), or polymerase chain reaction 194 195 (PCR), Fig. S2.2, S3.1-S3.4). We learned simplified predictive emulators for the OpenMalaria simulation results by training GP models on a limited set of simulated scenarios (Fig. 2B). We 196 show that the trained GP models accurately capture the dependencies between the disease model 197 input parameters and the output intervention impact, and are able to reliably predict the reduction 198 in *Pf*PR₀₋₉₉ attributable to any input intervention characteristics (Fig. 2B, S4.1-S4.3, Table S4.1). 199 200 Our work thus builds on recent applications of GPs in disease modelling and burden prediction for malaria (34). Using the trained GP emulator, through global sensitivity analysis, we evaluated 201 the key determinants of intervention impact (Fig. 2C). In addition, we performed a constrained 202 search for intervention and delivery profiles (TPPs) that maximize impact under a particular 203 health goal, given concrete, expert-informed, operational constraints such as possible 204 deployment coverage, or feasible intervention properties such as efficacy or duration of 205 protection (Fig. 2D). 206



208

209 Fig. 2 Quantitatively defining TPPs of novel disease interventions.

210 (A) Detailed schematic representation of the proposed quantitative framework to support

- 211 product development (full specifications in Materials and Methods). Figures (**B**)-(**D**) present the
- 212 results of applying the framework for an anti-infective malaria vaccine (mass administration,
- seasonal transmission with high indoor mosquito biting): (**B**) Correlation between simulated
- 214 true (x axis) and emulator predicted (y axis) $PfPR_{0.99}$ reduction with a GP emulator trained in a
- 215 cross-validation scheme (Pearson correlation coefficient r^2 distribution shown in boxplot) and
- validated on an out-of-sample test set (r^2 left upper corner and grey diamond on the boxplot in
- 217 the right lower corner). (C) Example vaccine impact determinants: the colors represent
- 218 proportions of the emulator output variance (relative importance) attributable to intervention
- 219 specifications, as well as health system access. (D) Example feasible landscape of optimal
- vaccine efficacy profiles for various health goals (minimum targeted PfPR₀₋₉₉ reductions, y axis).
- 221 For each health goal, the heatmap displays the minimum required efficacy when applied at a
- coverage of 60% and with a half-life of 7 months, assuming an access to care level of 25%
- 223 (example in the insert plot for a target reduction of at least 60%). Results in figures (C) and (D)
- 224 are displayed for a range of median simulated true $PfPR_{2-10}$ (before intervention deployment,
- 225 rounded values, x axis).

227 Intervention impact and the importance of their characteristics

With guidance from different groups of experts and partners (see definition of the various 228 stakeholders involved in Materials and Methods), we conducted an extensive analysis in the 229 230 malaria development space, covering a diverse spectrum of interventions pertaining to 1) antiinfective monoclonal antibodies 2) anti-infective vaccines, 3) transmission-blocking vaccines, 4) 231 outdoor attractive targeted sugar baits, and 5) eave tubes. Following simulation with 232 OpenMalaria of deployment of each of these interventions through mass administration 233 234 campaigns over several years (see Materials and Methods), we first analyzed the predicted distributions of reduction in true PfPR₀₋₉₉ (Fig. 3A, S3.2-S3.4). We found that, in general, when 235 236 aiming for substantial, prompt reductions in prevalence for this particular health target, vector control was by far the most impactful intervention across all settings. Monoclonal antibodies, 237 238 anti-infective and transmission-blocking vaccines had a more pronounced impact in lowtransmission settings compared to endemic settings (Fig. 3A, S3.1-S3.4, Table S5.1). 239 Sensitivity analysis indicated that the impacts of these interventions on malaria prevalence were 240

driven by different characteristics of their efficacy profiles, deployment strategies, or access to 241 care for treatment of clinical cases, for either short and long impact follow-up (Fig. 3B-E, S6.1 – 242 6.2). Across a large proportion of the simulated scenarios, over all parasite and vector targets and 243 interventions, coverage of the deployed intervention was overwhelmingly the primary driver of 244 impact especially in low transmission settings (Fig. 3B-E, S6.1-S6.2). For therapeutic 245 interventions, the impact of short-term passive immunizations such as monoclonal antibodies 246 relied on their deployment coverage and the health system (Fig. 3B, S6.1). In contrast, for long-247 acting interventions such as vaccines, impact was driven by deployment coverage and efficacy 248 (Fig. 3C, S6.1). Highly-efficient vector control interventions such as attractive targeted sugar 249 baits had a strong effect on prevalence (Fig. 3A), and their duration of effect was the most 250 important determinant (Fig. 3D, S6.2). The immediate impact of long-term vector control 251 252 interventions such as eave tubes was driven by deployment coverage, while their half-life was a key determinant for preventing resurgence (Fig. 3E, S6.2). 253

254





Fig. 3: Effects of novel malaria interventions on disease prevalence and their key drivers of impact.

- (A) Distribution of obtained reduction in $PfPR_{0.99}$ following deployment of various malaria
- 260 *interventions under development (shown with different colors) for a range of simulated*
- transmission settings (specified by median true $PfPR_{2-10}$ rounded values, x axis). Each boxplot
- 262 *displays the interquartile range (box), the median value (horizontal line), the largest and*
- smallest values within 1.5 times the interquartile range (whiskers), and the remaining outside
- values (points) of the $PfPR_{0.99}$ reduction values obtained across all the simulations for each
- 265 given setting. The remaining plots of the figure present the results of sensitivity analysis showing,
- across the same simulated $PfPR_{2-10}$ settings, the determinants of intervention impact on $PfPR_{0-99}$
- reduction for anti-infective monoclonal antibodies (**B**), transmission-blocking vaccines (**C**),
- 268 attractive targeted sugar baits (**D**) and eave tubes (**E**). Determinants of impact are shown for
- 269 both immediate and late follow-up, when interventions are applied once per year for three years
- 270 in a seasonal transmission setting with high indoor mosquito biting (full intervention
- 271 specifications provided in Materials and Methods and results for other settings and interventions
- 272 shown in Fig. S6.1-6.2 and Table S5.1).
- 273

274 Minimal requirements of novel malaria interventions to achieve a defined health goal

For the five aforementioned malaria interventions, we explored their optimal profiles for a broad 275 set of target *Pf*PR₀₋₉₉ reduction levels, creating landscapes of intervention profiles according to 276 277 their minimal characteristics across various transmission settings (Fig. 4-5, S7.1-S8.5). These landscapes provide a broad and comprehensive overview of the intervention potential 278 capabilities and limitations in achieving a desired health goal. For example, as opposed to an 279 anti-infective monoclonal antibody which requires high efficacy and duration to achieve large 280 281 *Pf*PR_{0.99} reduction in only a limited number of settings (Fig. 4A-B, S7.1-S7.2), attractive targeted sugar baits that kill mosquitoes achieve a wider range of target PfPR₀₋₉₉ reductions in high-282 transmission settings as well (Fig. 4C-D, S7.5). Similarly, while in settings with lower 283 transmission ($P_{f}PR_{2.5} < 30\%$), anti-infective and transmission-blocking vaccines had comparable 284 285 requirements in achieving similar $P_f PR_{0.99}$ reduction targets, anti-infective vaccines showed a higher potential and reached additional targets in high-transmission, endemic settings (Fig. 5). 286



288

Fig. 4: Estimated optimal intervention and delivery profiles (TPPs) for monoclonal 289 antibodies and attractive targeted sugar baits. 290

The heatmaps in figures (A) and (C) represent landscapes of optimal, constrained intervention 291

specifications (coverage, efficacy, and half-life) required to achieve a broad range of targeted 292

minimal reductions in $PfPR_{0.99}$ (y axis) across different simulated true $PfPR_{2.10}$ settings (rounded 293

values, x axis). Each intervention characteristic was minimized in turn, while keeping the other 294

characteristics fixed (values marked on each figure). Results are shown for an anti-infective 295 monoclonal antibody (A) and attractive targeted sugar baits (C). For a defined health goal of

296

297 reduction in $PfPR_{0-99}$ (dashed horizontal lines on figures (A) and (C)), the corresponding

minimum product profile requirements are shown for an anti-infective monoclonal antibody in 298 (B) and attractive targeted sugar baits in (D). Both figures (B) and (D) show how these

299

300 requirements change when these interventions are delivered at various frequencies (once or twice per year), and when the anti-infective monoclonal antibody is delivered in combination

301 with a blood-stage drug. The simulated health system access was 25%. Descriptions of all 302

intervention properties for identification of minimal profiles are detailed in Table S2.2, while 303

additional results for other settings and interventions are provided in Fig. S7.1-S7.6 and Table 304

305 *S*5.1.

307 For a detailed overview of landscapes of intervention profiles for all simulated settings and interventions see Fig. S7.1-S7.6. These landscapes together with the results of the sensitivity 308 309 analysis offer an evidence-based prioritization of resources during the product development process. For example, we found that while both efficacy and half-life are important for 310 immediate prevalence reductions with monoclonal antibodies, their effect is limited in preventing 311 resurgence and is only supported by high case-management levels (Fig. 3, 4, S6.1, S7.1-S7.2). 312 Conversely, the efficacy of anti-infective vaccines drives immediate impact, whereas half-life of 313 effect has greater importance for achieving and maintaining *Pf*PR₀₋₉₉ reductions (Fig. 3, 5, S6.1, 314 S7.3-S7.4). These results suggest that if vaccines and monoclonal antibodies are to support 315 preventing resurgence, then R&D efforts should focus on increasing and establishing antibody 316

317 longevity.

318 Our analysis shows that coverage is the primary driver of impact (Fig. 3B-E, S6.1-S6.2). This result has important implications for interventions requiring multiple applications to achieve high 319 efficacy, indicating that it is of crucial importance to target both vulnerable populations and the 320 proportion of the population missed by the intervention. While for some interventions high 321 322 coverage deployment might be very difficult or impossible to achieve, our analysis shows that 323 this can be alleviated by increasing the deployment frequency or through deploying combinations of interventions, which may have cost implications (Fig. 4B, 4D, 5B, 5D, S7.1-324 S7.5, S8.1-8.4). 325

We found that combining several interventions targeting different stages in the transmission 326 cycle can strongly affect the minimum requirements of a putative new intervention, potentially 327 increasing the impact of an otherwise weaker intervention. For example, for an anti-infective 328 329 monoclonal antibody with an initial half-life of 7 months and deployed at a coverage of 60% reflecting completion of multiple doses, achieving a prevalence reduction of 80% was impossible 330 when deployed once yearly for three years (Fig. 4A, S7.1). Furthermore, achieving the 331 332 aforementioned health goal required an efficacy of 80% when the intervention was deployed twice per year for three years (Fig. 4B, Fig. S7.2). However, when deployment of the 333 monoclonal antibody was coupled with a short half-life blood-stage parasite treatment such as 334 dihydroartemisinin-piperaquine or artemether-lumefantrine, its minimum required efficacy was 335 336 considerably reduced for both delivery frequencies (Fig. 4B, S7.1-S7.2, S8.1). Conversely, if we

assume an initial efficacy of 85% for the monoclonal antibody, we find that its minimal required

half-life can be reduced if we deploy this intervention in combination with the blood-stage

parasite clearing drug (Fig. 4B, S7.1-S7.2, S8.1). These results partly motivated the current


340 development of anti-infective monoclonal antibodies; use-cases will likely include deployment

341 with existing or new antimalarial treatment.

We also showed that a modified deployment schedule could reduce requirements for properties 342 of some interventions. For example, for highly-efficacious attractive targeted sugar baits, higher 343 344 coverage and half-life were required when implemented once per year for three years compared with an accelerated delivery schedule of twice per year for three years (Fig. 4C-D). Except for 345 high transmission settings ($P_{f}PR_{2-10} > 41\%$), a minimum required efficacy of 70% was sufficient 346 to attain the desired health goal for the majority of settings and for both delivery schedules (Fig. 347 4C-D, Fig. S7.5, Fig. S8.4). This result is also reflected in the sensitivity analysis (Fig. 3D). 348 Accordingly, the variation in intervention efficacy in the ranges investigated has little importance 349 in driving the intervention impact and suggests that, once a vector control intervention such as 350 attractive targeted sugar baits achieves a high killing efficacy (here greater than 70%), a next step 351 352 of optimizing other intervention characteristics such as deployment coverage or duration leads to a higher impact. These results demonstrate the strength of our analysis in identifying the 353 intervention characteristics to be prioritized for R&D. 354

When coupled with a short half-life blood-stage parasite treatment, requirements of coverage, 355 efficacy and half-life were reduced also for anti-infective and transmission blocking vaccines to 356 achieve the targeted reductions of PfPR₀₋₉₉ (Fig. 5, S7.3-7.4, S8.2-S8.3). In particular for high-357 transmission settings ($PfPR_{2.5}>25\%$), given an RTS,S-like half-life of 7 months, both anti-358 infective and transmission-blocking vaccines could not achieve any of the defined prevalence 359 reduction goals if deployed singly. This was the case for any deployment coverage given an 360 initial efficacy of 85% as well as for any efficacy given a deployment coverage of 60%. 361 362 Combining vaccine deployment with a blood-stage drug not only significantly expanded the achievable health targets also to high-transmission settings, but also reduced vaccine properties 363 requirements. Our analysis reveals that anti-infective vaccines had a higher potential than 364 transmission-blocking vaccines, requiring less performance and achieving higher prevalence 365 366 reductions targets also in higher transmission settings. When combined with blood-stage parasite

- treatment, the coverage, efficacy and half-life requirements of anti-infective vaccines were lower
- 368 compared to those of transmission-blocking vaccines for the same prevalence reduction targets
- 369 (Fig. 5, S7.3, S7.4, S8.2, S8.3).
- 370 Our comprehensive analysis was applied to explore determinants of impact and required profiles
- of interventions across two seasonal settings (seasonal and perennial) and three types of
- 372 mosquito biting patterns (low, medium and high indoor biting). A detailed overview of impact
- determinants and optimal intervention profiles is presented in the Supplementary Materials (Fig.
- 374 S6.1-S8.5, and additional key results summarized in Table S5.1).



376

377 Fig. 5. Estimated optimal intervention and delivery profiles (TPPs) for anti-infective and

transmission blocking vaccines deployed once per year with or without a blood stage

379 **clearing drug.**

380 The heatmaps in figures (A) and (C) represent landscapes of optimal, constrained intervention

characteristic profiles (coverage, efficacy, and half-life) required to achieve various health goals

- 382 (quantified by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2.10}$
- 383 settings (rounded values, x axis). Each intervention characteristic was minimized in turn, while
- 384 keeping the other characteristics fixed (values marked on each figure). Results are shown for an
- anti-infective vaccine (A) and a transmission blocking vaccine (\vec{C}). Given a defined health goal
- of reduction in $PfPR_{0.99}$ (minimum 70% reduction, dashed horizontal lines on figures (A) and
- (*C*)), the corresponding minimum product profile requirements are shown for the same two
- interventions, i.e., for an anti-infective vaccine in (**B**) and transmission blocking vaccine in (**D**).
- Both figures (**B**) and (**D**) show how the minimum required profiles change when these
- interventions are delivered in combination with a blood-stage drug. The simulated case
- 391 management level (E_5) for all the displayed optimization analyses was assumed 25%. The
- 392 descriptions of all intervention properties for identification of minimal profiles are detailed in
- 393 Table S2.2.
- 394

396 **Discussion**

In this study, we introduced a new modeling and machine-learning framework that for the first 397 time enables quantitative differentiation between operational, setting, and intervention 398 parameters as determinants of intervention impact, using detailed simulation models of disease. 399 Our framework can be used for any disease where a valid model of disease progression or natural 400 history of disease is available. We provided mathematical tools for efficiently and quantitatively 401 defining the minimum profiles of malaria interventions as well as delivery approaches required 402 403 to reach a desired health goal. Furthermore, our methodology provides a means to refine the identified optimal efficacy and duration characteristics as additional information becomes 404 available. As a result, we can apply fully-detailed disease models to direct the design of novel 405 interventions and understand how intervention-specific, epidemiological and systems factors 406 407 jointly contribute to impact and thus inform TPP guidance. Most immediately, the approach is 408 highly relevant to define successful interventions against emerging diseases such as SARS-CoV-2, and to support efficient, fast development of operational strategies. As uncertainties in disease 409 progression and epidemiology can be incorporated in our approach, it also provides a way to 410 systematically sort through large complex landscapes of unknowns and thus refine properties of 411 interventions or clinical trials as more knowledge is available. 412

The value of our approach is realized through iterative collaboration with product development 413 experts, to perform model-based guidance throughout the development process, and refine 414 415 feedback on model predictions as interventions progress through development. For malaria, where multiple interventions are in development, it also offers an approach for product 416 developers from diverse fields (such as therapeutics and insecticide development) to collaborate 417 and incorporate knowledge of other interventions into their TPP development. Although in our 418 analysis we used reduction of $P_{f}PR_{0.99}$ as a health goal, our method can be applied to other 419 disease burden statistics as required. The same rationale applies for investigation of other 420 deployment strategies, required doses of interventions or further intervention combinations. 421 While also bringing valuable quantitative insights to guide product development, our analysis of 422

while also bringing valuable quantitative insights to guide product development, our analysis of
novel malaria interventions reproduces previous findings concerning intervention characteristics
which are key drivers of impact. Previous studies have shown that intervention coverage is a
major determinant of impact in the context of mass drug administration (*17*), of vaccines (*35*) as

well as vector control (36). Furthermore, our analysis reaffirms previous work showing the 426 ability of vector control interventions to achieve substantial reductions in malaria burden (37). 427 Our approach constitutes a powerful tool to help address the challenges of current malaria 428 strategies and develop new interventions to progress towards malaria elimination. While 429 currently promising interventions such as insecticide treated nets, seasonal malaria 430 chemoprevention (SMC) and intermittent preventative treatment (IPT) have been very successful 431 at reducing malaria incidence and saving lives, their improved burden reduction and future 432 433 success is currently challenged by limited adherence, resource and time constraints to increase coverage and usage in underserved populations, as well as resistance (38). Furthermore, for 434 settings where SMC has not been implemented or not recommended (for example in East Africa 435 or in perennial settings), there remains a gap in available interventions to protect vulnerable 436 populations who experience the highest burden of malaria. Similarly, for settings with outdoor 437 438 biting mosquitoes, the development and rollout of novel vector control interventions is needed. New therapeutics and immune therapies suitable for seasonal delivery such as long-acting 439 injectables or monoclonal antibodies are currently being developed that may close one of these 440 gaps (39, 40). However, in order to efficiently make decisions on their development, guidance on 441 their key performance characteristics and definition of their TPP documents is needed from early 442 stages. Our quantitative framework can support the development of interventions from the 443 444 beginning by generating the evidence to inform and define evaluation criteria ensuring new products meet relevant health targets, while considering how these products may affect disease 445 burden and epidemiology within a population. As we show here, this relies on iterative dialogue 446 with stakeholders, to first define health targets, simulated scenarios, achievable intervention 447 properties and operational settings. The modelling part of the framework incorporates all this 448 information as well as relevant disease transmission dynamics, building an in-silico system for 449 testing the developed intervention. Next, the sensitivity analysis part of the framework informs 450 which intervention characteristics drive impact and are thus crucial in achieving the defined 451 health goal, providing insights on the development processes to be prioritized. Finally, the 452 optimization analysis part of the framework reveals the potential of the developed intervention 453 and how its efficacy and coverage requirements change according to the defined health targets 454 and deployment setting. The landscapes of intervention profiles help product developers to gauge 455 development and investment efforts and select promising products. Furthermore, our approach 456

allows investigating combinations of new and existing interventions, identifying alternatives to
alleviate shortcomings such as coverage limitations. To achieve a final TPP, several iterations of
the analysis are required, to ensure that the optimal tradeoffs between intervention capabilities
and target goals for a given setting are achieved.

As with all modelling studies, our approach is exposed to several limitations. The provided 461 quantitative estimations in this study incorporate an increased level of uncertainly due to the 462 additional emulation layer and are dependent on the performance of the trained emulator. We 463 464 addressed this challenge with extensive adaptive sampling and testing to ensure a high level of accuracy of the trained emulators (Fig. 2, S4.1-S4.3, Table S4.1). Despite the intrinsic 465 uncertainty, the framework is intended to provide guiding principles and an efficient means of 466 exploring the space of intervention characteristics which otherwise would not be possible. 467 Evidently, our analysis relies on the disease model assumptions of disease and transmission 468 469 dynamics as well as expert opinion of likely intervention parameterizations in absence of clinical knowledge. Lastly, the current analysis explored a subset of use-cases, transmission settings and 470 471 intervention combinations. Future work should focus on the likely settings and relevant use cases as the interventions are being developed and their TPP documents refined. 472 Moving beyond the work presented in this paper, our framework would allow combining 473

simulation models with other sources of data describing geographical variation in disease, for 474 example, modelled health systems or modelled prevalence (41, 42) and to incorporate 475 476 interactions of interventions with novel interventions for surveillance. Clinical trials for new interventions could thereby be prioritized to geographical settings, where public health impact is 477 likely to be maximized and where appropriate, to inform decisions on achieving non-inferiority 478 or superiority endpoints (43, 44). A significant extension is incorporating economic 479 considerations which may affect development decisions, including both costs of R&D, as well as 480 implementation and systems costs for final deployment. 481

482

483 Materials and Methods

The approach introduced here combines infectious disease modeling with machine learning to understand determinants and define quantitative properties of target product profiles of new

We used OpenMalaria (33, 45), an open source stochastic individual-based model to

486 malaria interventions. The building blocks and methodology of the approach are schematically

487 outlined in Fig. 2 which guides the following sections of Materials and Methods.

488 **<u>1 Description of the disease model</u>**

489 **1.1 Individual-based model of malaria transmission**

simulate malaria epidemiology and transmission dynamics across humans and mosquitoes in 491 various settings. OpenMalaria considers the natural history of malaria in humans linked with a 492 deterministic, entomological model of the mosquito oviposition cycle and malaria transmission 493 in mosquitoes (46, 47) (Table S1.1). The modelled transmission cycle (Fig. 1) considers the 494 chain of processes following infection of a human host, simulating malaria infection in 495 individuals and modelling infection characteristics such as parasite density, duration of infection, 496 infectivity to mosquitoes, and health outcomes such as morbidity, mortality or anemia. 497 OpenMalaria specifically captures heterogeneity in host exposure, susceptibility and immune 498 response, taking into consideration the effects of several factors such as acquired immunity, 499 human demography structure, or seasonality (48-51). Furthermore, the model includes a detailed 500 representation of the health system (52), and of a wide range of human and vector control 501 interventions while tracking multiple health outcomes over time (Fig. 1, Table S1.1). 502 OpenMalaria has been widely documented and validated against a multitude of field 503 studies, compared to existing models and used in extensive studies to provide evidence for the 504 505 epidemiological effects of various interventions(10, 29, 33, 53-55). It comprises 14 model variants based on distinct sets of assumptions on its epidemiology and transmission components 506 (45). For the present analysis, the "base" simulation model was used. The mathematical 507 equations of the model, its assumptions and calibrations have been thoroughly described in 508 509 numerous previous publications, therefore are not specified here, however, an overview of the

510 OpenMalaria modelled processes and assumptions along with the corresponding references are 511 provided in Table S1.1.

512

490

513 **1.2 Calibration of the disease model and description of simulation experiments**

514 OpenMalaria has been calibrated and validated in previous studies using historical 515 epidemiological data (*29, 33, 45*). The present analysis uses a previously-calibrated version of

the model which reflects demographics, epidemiology, entomology, health system and

seasonality of a health facility catchment area in Tanzania (50, 52, 56).

The simulated human population size in this analysis was 10'000 individuals, with its age structure informed by data collected from a health and demographic surveillance site in Ifakara, Tanzania, available through the INDEPTH network (*57*). For all simulations, we assumed there were no imported infections during the whole study period.

Health system characteristics (Table S1.1) were defined through parameterization of a case management model based on data provided by the Tanzanian National Malaria Control Program (*52*). To define the simulated case management level, the probability of effective cure within two weeks from the onset of fever (E_{14}) was varied within the interval [0 - 0.8] corresponding to a probability of seeking care (access to treatment) within 5 days from the onset of fever (E_5) within the interval [0.04 - 0.5] (*53*). During the model simulations, the case management level was constant over time.

Mosquito entomological parameters and seasonal exposure patterns were estimated from 529 field studies conducted in the Namawala and Michenga villages located nearby Ifakara in 530 531 Tanzania (58, 59). Two archetypal seasonal settings were simulated: a seasonal exposure setting with one transmission peak in September estimated from the mentioned field studies (Fig. S2.1), 532 and a perennial setting with uniform, constant exposure throughout the year. Two mosquito 533 species were present in the simulated settings: endophagic (indoor-biting, human blood index 534 535 equal to 0.99) and exophagic (outdoor-biting, human blood index is 0.5), respectively. The ratios between the population sizes of indoor and outdoor mosquito species were classified into three 536 levels corresponding to high (indoor proportion is 0.8 out of total mosquito population), mid 537 (indoor proportion is 0.5) and low indoor biting (indoor proportion is 0.2). The extent of malaria 538 539 transmission in each simulation was defined by the yearly entomological inoculation rate (EIR). For each simulation, EIR was sampled from the interval [1, 25] leading to a simulated range of 540 Plasmodium falciparum parasite rate or prevalence (PfPR) distributions across the various 541 transmission settings (Figures S2.1, S2.2, Table S2.1). 542

543

544 **1.3 Definition of intervention profiles**

545 Adopting a holistic view, we built an agnostic, standardized representation for each 546 malaria intervention. Accordingly, a malaria intervention was characterized through the targets

of the transmission life cycle it affects, along with the efficacy, half-life and decay of its effect 547 (Figure 1, S2.3, Table S2.1). The efficacy of a therapeutic intervention was quantified by its 548 549 ability to clear parasites or prevent infection, while for mosquito-targeted interventions (vector control tools) it corresponded to the ability of the intervention to kill or prevent mosquitoes from 550 biting human hosts. For each intervention, its efficacy decayed over time according to a specific 551 decay type (defined in Fig. S2.3). The coverage of interventions was quantified by the 552 percentage of the population affected by the respective intervention. Geographical setting 553 characteristics such as entomological inoculation rates (EIR), seasonality, case-management 554 coverage, as well as transmission and vector characteristics were also included in the simulation 555 specifications (Fig. 1, Table S2.1). 556 We defined the following intervention targets in the transmission cycle (Fig. 1): 557

558 - Anti-infective: acts at the liver stage and prevents occurrence of a new infection

559 - Blood stage clearance: clears blood-stage parasites by administration of a drug

560 - **Transmission blocking:** prevents parasite development into gametocytes

Mosquito life-cycle killing effect: kills mosquitoes during different stages of their life cycle,
 such as, for example, before a blood meal (pre-prandial killing) and/or after a blood meal
 (post-prandial killing). Furthermore, mosquitoes are affected by vector control interventions
 according to their indoor and outdoor biting patterns.

The length of the intervention effect was described via either half-life for exponential, sigmoidal or biphasic decay profiles, or by duration for step-like decay profiles. Generally, halflife refers to half-life of intervention efficacy decay, representing the time in which the initial intervention efficacy has been reduced by 50% (Fig. S2.3, Table S2.1). As opposed to half-life, the duration of effect is equivalent to the entire decay time. For simplicity, since only one intervention had a step-like decay, we use the words half-life and duration interchangeably.

To define the breadth, range and profiles of simulated malaria interventions, we collaborated with end users at the Bill & Melinda Gates Foundation and the product development partnerships PATH's Malaria Vaccine Initiative (PATH-MVI) and Innovative Vector Control Consortium (IVCC). For each new intervention in the portfolio of PATH-MVI, IVCC and others, we undertook several expert discussion groups to catalogue the ranges of potential effectiveness; potential delivery strategies; parasite or vector targets; the likely properties in terms of action (target), efficacy, duration and decay; and use cases/delivery (age target, mass intervention,

578 yearly deployment or other). These results are summarized in Table S2.1 which presents a 579 comprehensive description of all intervention characteristics, parameter values, as well as the 580 ranges they were varied within. Setting-specific characteristics used for the different simulated 581 scenarios are also summarized in Table S2.1.

In our current study, each intervention or combination of interventions was applied as 582 mass intervention targeting all ages equally, along with continuous case management. In this 583 analysis, we did not examine targeting particular populations or age groups to develop our 584 approach. The deployed mass intervention packages followed a long period of model warm up 585 (150 years), and were implemented in June and/or December for three years (Fig. S3.1). 586 Coverage at deployment time refers to the percentage of the population covered by the 587 intervention's initial efficacy, irrespective of how many doses/applications are required to reach 588 that coverage, assuming that the necessary doses have previously occurred. 589

590

591 **1.4 Translation of input EIR to** *Pf***PR**₂₋₁₀ **and** *Pf***PR**₀₋₉₉

For each simulation, OpenMalaria requires the definition of the intensity and seasonality 592 593 of malaria exposure specified through the input EIR level and its yearly profile in the absence of interventions (Fig. S2.1). EIR is an appropriate measure for reflecting transmission intensity 594 (60), however it is difficult to measure in the field and its interpretation in the context of 595 intervention impact is difficult to apprehend when looking at the effects of drugs and vaccines 596 597 (61, 62). For this reason, although EIR is the force of infection input to all OpenMalaria simulations, we report simulation outcomes and downstream analyses at the corresponding 598 median $PfPR_{2-10}$ and $PfPR_{0-99}$ before the interventions are deployed. We report true infection 599 prevalence and not patent PCR or RDT-detected. To do so, we discretized the continuous EIR 600 601 space into discrete unit-wide intervals and the median PfPR was calculated across the obtained *Pf*PR for all simulations in each discrete interval (Fig. S2.2). 602

603

604 **1.5 Definition of impact and health goals**

A comprehensive set of simulated scenarios was built by sampling uniformly the parameter space of setting and intervention characteristics. To estimate the impact of the deployed interventions, in each simulation, we calculated the reduction in $PfPR_{0.99}$ attributable to the deployed intervention. $PfPR_{0.99}$ reduction was calculated by comparing the initial average

prevalence in the year before any interventions were deployed to the average yearly prevalence 609 obtained in the first year (short follow-up) and in the third year (long follow-up) after 610 deployment of interventions (Fig. S3.1). Consequently, the defined health goals corresponded to 611 a given minimum threshold of $PfPR_{0.99}$ reduction that the deployed interventions should achieve. 612 Figures S3.2 - S3.4 present the distributions of obtained *Pf*PR₀₋₉₉ reduction for the 613 OpenMalaria simulation experiments covering all the interventions and deployments investigated 614 in the present study. In seasonal, low transmission settings (EIR < 2) a proportion of simulations 615 reached elimination before any intervention was deployed and were removed from the analysis 616 (Fig. S3.5). Since this happened for over 75% of simulations at EIR<2, we did not investigate 617 optimal intervention profiles for transmission settings with EIR<2. Arguably, for these settings 618 close to elimination, a different health goal, such as probability of elimination, would be more 619 appropriate which is not within the scope of the present study focusing on $PfPR_{0.99}$ reduction. 620 621

622 <u>2 Building a disease model emulator with Gaussian processes</u>

As it was computationally intensive and challenging to run an exhaustive number of 623 624 simulations in order to explore with OpenMalaria all the parameter space for diverse combinations of interventions, settings and deployments, we applied machine learning 625 techniques and kernel methods to leverage our analysis. Precisely, starting from a training 626 dataset of simulations generated with OpenMalaria, we used Gaussian process (GP) models (24) 627 628 to infer the relationship between simulation variables (e.g., intervention coverage, half-life, efficacy, etc.) and corresponding intervention impact ($P_{f}PR_{0.99}$ reduction). This approach 629 allowed us to build a fast, simplified predictive model that could provide estimates of the disease 630 model output for any new inputs without running new OpenMalaria model simulations. 631 632 Gaussian process models are non-parametric models which define a prior probability distribution over a collection of functions using a kernel, smooth function. Precisely, given the 633

634 relationship

 $y = f(x) + \varepsilon$

where *y* in our case is the *Pf*PR₀₋₉₉ reduction and *x* represents the set of intervention parameters x_1, \ldots, x_n , the main assumption of a GP is that

$$P(f(x_1), f(x_2), \dots, f(x_n)) \sim N(\mu, \Sigma)$$

637 where

$$\Sigma_{x_i,x_j} = K(x_i,x_j)$$

is the covariance matrix of the Gaussian distribution, μ is its mean and K is a kernel function (24). Once data is observed, the posterior probability distribution of the functions consistent with the observed data can be derived which is then used to infer outcomes at unobserved locations in the parameter space (24). The intuition behind a GP model is based on the "smoothness" relationship between its components. Accordingly, points which are close in the input parameter space will lead to close points in the output space.

644

645 **2.1 Training data**

For each intervention and setting, a training dataset was built using discrete Latin hypercube 646 uniform sampling (63) across the input parameter space (defined in Table S2.1). Ten stochastic 647 realizations (replicates) of each sampled data point were considered. OpenMalaria was run on the 648 sampled data points and $PfPR_{0.99}$ was calculated for both short and long follow-up. The size of 649 the training set was varied between 10 and 1000 points (100 – 10000 including replicates) for 650 several simulation experiments (Fig. S4.1) and the performance of the trained GP was assessed 651 via the Pearson correlation coefficient r^2 . The minimum training set size which led to $r^2 > 0.95$ 652 was selected for the remaining simulation experiments. 653

654

655 **2.2 Gaussian process emulators**

For each transmission setting and intervention, a GP model with a Gaussian kernel was
trained in a 5-fold cross-validation scheme using the training set with OpenMalaria simulations.
For training the GP, we used the R package *HetGP* version 1.1.1 (*64*, *65*). HetGP is a powerful
implementation of GP models, featuring heteroskedastic GP modeling embedded in a fast and
efficient maximum-likelihood-based inference scheme.

GP performance was assessed by calculating the correlation between true and predicted outputs on out-of-sample test sets as well as the mean squared error (Fig. S4.2 – 4.3, Table S4.1). Precisely, the training set was split in 5 subsets and, iteratively, 4 of these subsets were used for training the GP, while the remaining one was used as an out-of-sample test set during the crossvalidation procedure. After assessing the prediction error during the cross-validation procedure, the GP was trained using the entire training set. Furthermore, since the trained GP model provides the mean and variance of each predicted output, we used this probabilistic

representation to assess the uncertainty of the trained model across the entire parameter space

and to refine the GP model through adaptive sampling (66-68). Accordingly, we iteratively

sampled new training points from high-uncertainty regions of the parameter space and updated

the model with the new training samples until the correlation between true and predicted values

on an out-of-sample test set reached a plateau. Finally, a separate out-of-sample test set was built

to assess the overall performance of the GP (Fig. S4.2 - 4.3, Table S4.1).

674

675 <u>3 Identifying impact determinants through sensitivity analysis</u>

In order to estimate the contribution of each model input and its interactions with the other inputs to the variance of the model outcome, we conducted a global sensitivity analysis based on variance decomposition (*69*). This analysis shows which input parameters have higher impact on the model outcome. It relies on the decomposition of the output variance in a sum of individual input parameter conditional variances:

$$Var(Y) = \sum_{i} V_{i} + \sum_{i} \sum_{j>i} V_{ij} + \dots + V_{12\dots d}$$

where Y is the model outcome (in our case, $P_f PR_{0-99}$ reduction), d corresponds to the number of model inputs, and the conditional variances are defined as:

$$V_{i} = Var(E(Y|x_{i}))$$
$$V_{ij} = Var(E(Y|x_{i}, x_{j})) - V_{i} - V_{j}$$
$$V_{ijk} = Var(E(Y|x_{i}, x_{j}, x_{k})) - V_{ij} - V_{jk} - V_{ik} - V_{i} - V_{j} - V_{k}$$

683

684 with x_1, \ldots, x_n representing the model input parameters.

Based on the above decomposition of output variance, the first order sensitivity index is defined as:

$$S_i = \frac{V_i}{Var(Y)}$$

and corresponds to the proportion of output variance assigned to the main effect of X_i, i.e.,

regardless its interactions with other model inputs (69, 70).

To account for the contribution of each model input as well as the variance of its interactions with other inputs to the variability of the model output, the total effect sensitivity index is used:

$$T_i = 1 - \frac{Var(E(Y|x_{\sim i}))}{Var(Y)}$$

where the notation \sim i stands for all indices except i (69, 70).

In the above decomposition of model output variance, by replacing the expressions of thesensitivity indexes, the following properties can be deduced:

$$\sum_{i} S_{i} + \sum_{i} \sum_{j>i} S_{ij} + \dots + S_{12\dots d} = 1$$

695

and

$$\sum_i T_i \geq 1$$

To compute the sensitivity indexes, we use the function "soboljansen" from the R package "sensitivity" (*71*). The function estimates the sensitivity indices through MCMC sampling, using a Monte Carlo approximation for computing conditional expectations. Within the sampling scheme, we sampled 100'000 points to estimate the sensitivity indices.

Calculating the sensitivity indices defined above, the variance of the GP emulator output was thus decomposed into proportions attributable to intervention characteristics, i.e., intervention efficacy, half-life and deployment coverage, as well as access to care. Using the main effects, we defined the relative importance r_i of each characteristic as a proxy for impact determinants as follows:

$$r_i = \frac{S_i}{\sum_{i=1}^d Si}$$

where d is the number of intervention characteristics and $\sum_{i=1}^{d} r_i = 1$.

706 **<u>4 Finding minimal intervention properties</u>**

The trained GP models for each transmission setting and intervention were used within a general-purpose optimization scheme in order to identify minimum intervention properties that reach a defined $PfPR_{0.99}$ reduction goal given operational and intervention constraints.

710 Let

$$g(\mathbf{x}) = g(x_1, x_2, x_3, x_4)$$

denote the GP model predicting the mean prevalence reduction obtained after deploying an

intervention with given characteristics in a transmission setting, with

$$x_1 = tool \ coverage$$

 $x_2 = tool \ half - life$

> $x_3 = tool \, efficacy$ $x_4 = access \, to \, treatment.$

For various levels of $PfPR_{0.99}$ denoted with p_k , each intervention characteristic was optimized separately, keeping the remaining characteristics as well as the level of case management fixed to pre-set levels. Precisely, the optimization procedure searches for

 $\min(x_i) | x_{\sim i}$

such as

 $g(\mathbf{x}) \ge p_k$

717 with the constraints:

 $l_i \leq x_i \leq u_i$

where l_i and u_i are the lower and upper bounds of x_i , respectively and the notation $\sim i$ is used to represent all the characteristics except *i*. A detailed description of the parameter specifications during optimization for each intervention is provided in Table S2.2.

To solve the above optimization problem, we used a general nonlinear augmented 721 Lagrange multiplier method (72, 73) implemented in the R package "Rsolnp" (74). To ensure 722 optimality of the obtained solutions and avoid local minima, 10 random restarts were chosen 723 among 1000 uniformly-sampled input parameter sets and the optimization procedure was run 724 separately for each restart (implemented in function "gosolnp" in the same R package). To 725 capture the variance of the optimal intervention profile, since the output of a GP model is a 726 distribution, we solved the above optimization problem for several cases and we report the 727 distribution of the obtained minima when: 728

(i)
$$g(\mathbf{x}) = \mu$$

(ii) $g(\mathbf{x}) = \mu \pm \sigma$
(iii) $g(\mathbf{x}) = \mu \pm 2\sigma$

where μ is the predicted mean of the GP model and σ is the standard deviation. Where the nonlinear optimization algorithm did not find any solutions, we performed an additional fine grid search of 10000 uniformly-sampled data points.

In seasonal settings, at low transmission (simulated EIR < 2, corresponding simulated true $PfPR_{2-10} < 11.7\%$), over 75% of simulations reached malaria elimination ($PfPR_{0-99} = 0$) under the simulated levels of case management, before intervention deployment (Fig. S3.5). For this reason, the space of obtained prevalence reductions following intervention deployment was

- rather sparse and the obtained optima were not reliable and often did not converge. Therefore,
- we chose to report minimum intervention profiles for settings with true $PfPR_{2-10} \ge 11.7\%$ (with
- RDTs this yields a patent $PfPR_{2-10} \ge 5.8\%$).
- 739

740 **<u>5 Iterative communication with stakeholders</u>**

During the development of our methodological framework, we actively engaged in regular 741 742 communication and exchanges with different expert groups. The stakeholders involved in these 743 discussions were the Bill and Melinda Gates Foundation (BMGF), the Innovative Vector Control Consortium (IVCC) and the PATH's Malaria Vaccine Initiative (PATH-MVI). Coordinated by 744 BMGF, these exchanges ensured a crucial discussion environment, aiding and guiding the 745 methodology at various levels: intervention profiling, and defining relevant intervention use 746 747 cases, and product characteristics. Furthermore, the framework has been presented and validated 748 in presence of the stakeholders in successive meetings. These discussions contributed towards refining the investigation of various intervention profiles and led to exploration of intervention 749 750 combinations. Subsequently, the iterative exchanges with the stakeholders have not only shaped but also proven the value of our methodological framework in its versatility to adapt addressing 751 752 relevant questions along the product development pathway.

753

754 Acknowledgments:

We would like to thank Lydia Burgert, Theresa Reiker, Andrew Shattock, Thomas Smith, and

756 Dylan Muir for insightful discussions and feedback on the developed methodology and the

manuscript. We would also like to thank Thomas van Boeckel and Amalio Telenti for providing

useful feedback on the manuscript. Calculations were performed at sciCORE

(<u>http://scicore.unibas.ch/</u>) scientific computing core facility at University of Basel. We would

further like to thank collaborators at the Innovative Vector Control Consortium (IVCC), PATH's

761 Malaria Vaccine Initiative (MVI) and Joerg Moehrle from Medicines for Malaria Venture

(MMV) for their insightful discussions and feedback on the model scenarios. This work has been

possible thanks to the Malaria Team at the Bill and Melinda Gates Foundation who facilitated

exchanges with the product development partners and supported model scenarios and

- ⁷⁶⁵ interpretations. In particular, we would like to thank Scott Miller, Jean-Luc Bodmer, Laura
- Norris, Bruno Moonen, Dan Strickman, and Philip Welkhoff.

767	Funding: This work was supported by the Bill and Melinda Gates Foundation (OPP1170505 to
768	MAP) and the Swiss National Science Foundation (PP00P3_170702 to MAP);
769	
770	Author contributions: M.G., G.Y. and M.A.P conceived the study, designed the simulation
771	experiments, developed methodology and analyzed the results. F.C., E.C., and N.C. provided
772	methodological expertise. E.M.S., N.H., M.M., and S.R contributed with their expertise
773	regarding product development, intervention properties and guided analysis. M.G., G.Y., M.A.P.
774	wrote the manuscript. All authors provided continuous feedback and approved the final
775	manuscript;
776	
777	Competing interests: All authors declare no competing interests;
778	
779	Data and materials availability: All the analysis code used in the paper as well as
780	corresponding documentation, parameterizations and configuration files for the software
781	workflow necessary to generate the simulation data with OpenMalaria and reproduce the analysis
782	are available at <u>https://github.com/SwissTPH/TPP_workflow</u> .
782	are available at <u>https://gittldb.com/Swiss111/111_worknow</u> .
784	
	Supplementary Materials are below following the references
785 786	
787	List of Supplementary Figures and Tables
788	The following supplementary Figures and Tables complement the analysis and results reported in the main manuscript and are organized as follows:
789 790	 the main manuscript and are organized as follows: Description of the malaria disease transmission dynamics (OpenMalaria) model components
791	and assumptions:
792	• Table S1.1. Overview of the OpenMalaria model components.
793	• Simulated malaria transmission dynamics in the presented analysis:
794	• Fig. S2.1. Illustration of the yearly malaria transmission and prevalence patterns
795	in simulated seasonal settings.
796 797	• Fig. S2.2. Simulated distributions of true and patent (detected with PCR or RDT) $PfPR_{0.99}$ and $PfPR_{2-10}$ for various input EIR levels in absence of interventions.
797 798	 Parameterizations of simulated malaria interventions and their optimization setup:
799 799	• Fig. S2.3. Representation of decay and the range of efficacy and half-life against
800	different parasite or vector targets for intervention-agnostic malaria interventions.
801	• Table S2.1. Description and ranges of simulation variables.
802	• Table S2.2. Specifications of the optimization procedure for TPP development.
803	Simulation outputs:

804		0	Fig. S3.1. Examples of OpenMalaria simulation outputs.
805		0	Fig. S3.2. Distributions of prevalence reduction following yearly deployment of
806			single interventions.
807		0	Fig. S3.3. Distributions of prevalence reduction following yearly deployment of
808			combinations of interventions.
809		0	Fig. S3.4. Distributions of prevalence reduction following deployment of single
810			and combinations of interventions twice per year.
811		0	Fig. S3.5. Simulations reaching malaria elimination before intervention
812			deployment.
813	•	Emulator	training and evaluation:
814		0	Fig. S4.1. Assessment of the performance of the trained GP depending on the
815			training set size.
816		0	Fig. S4.2. Performance of the trained GP emulators predicting immediate
817			intervention impact.
818		0	Fig. S4.3. Performance of the trained GP emulators predicting long-term
819			intervention impact.
820		0	Table S4.1. Performance of the trained Gaussian Process emulators predicting
821			immediate and long-term intervention impact.
822	•	Summary	of analysis results for all simulated transmission settings and interventions:
823		o	Table S5.1. Key findings guiding target product profiles of new malaria
824			interventions.
825	•	Sensitivit	y analyses and impact determinants of interventions:
826		0	
827			different transmission settings.
828		0	Fig. S6.2. Key drivers of impact for vector control malaria interventions across
829			different transmission settings.
830	•	Feasible l	andscapes of optimal, constrained intervention profiles (TPPs) for achieving a
831			ealth goal across different transmission settings and operational factors:
832		0	Fig. S7.1 Feasible landscapes of optimal, constrained intervention profiles (TPPs)
833		-	for an anti-infective monoclonal antibody deployed once per year.
834		0	Fig. S7.2. Feasible landscapes of optimal, constrained intervention profiles
835		C C	(TPPs) for an anti-infective monoclonal antibody deployed twice per year.
836		0	Fig. S7.3. Feasible landscapes of optimal, constrained intervention profiles
837		-	(TPPs) for an anti-infective vaccine deployed once per year.
838		0	Fig. S7.4. Feasible landscapes of optimal, constrained intervention profiles
839		C C	(TPPs) for a transmission-blocking vaccine deployed once per year.
840		0	Fig. S7.5. Feasible landscapes of optimal, constrained intervention profiles
841		C C	(TPPs) for attractive targeted sugar baits deployed once or twice per year.
842		0	Fig. S7.6. Feasible landscapes of optimal, constrained intervention profiles
843		-	(TPPs) for eave tubes deployed once per year.
844	•	Minimum	profiles of interventions for achieving a desired health goal across different
845			ion settings and operational factors:
846		0	Fig. S8.1. Optimal intervention profiles (TPPs) for anti-infective monoclonal
847		0	antibodies under various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at
848			least 70%.
5.5			

849		• Fig. S8.2. Optimal intervention profiles (TPPs) for anti-infective vaccines under		
850		various deployment regimes to achieve a $PfPR_{0-99}$ reduction of at least 70%.		
851		• Fig. S8.3. Optimal intervention profiles (TPPs) for transmission-blocking		
852		vaccines under various deployment regimes to achieve a <i>Pf</i> PR ₀₋₉₉ reduction of at		
853		least 70%.		
854		• Fig. S8.4. Optimal intervention profiles (TPPs) for attractive targeted sugar baits		
855		under various deployment regimes to achieve a <i>Pf</i> PR ₀₋₉₉ reduction of at least 70%.		
856		• Fig. S8.5. Optimal intervention profiles (TPPs) for eave tubes to achieve a $PfPR_{0}$ -		
857		⁹⁹ reduction of at least 70%.		
858				
859	References and Notes:			
860				
861	1.	P. Cocco, A. Ayaz-Shah, M. P. Messenger, R. M. West, B. Shinkins, Target Product		
862		Profiles for medical tests: a systematic review of current methods. BMC medicine 18, 1-		
863		12 (2020).		
864	2.	A. Brooks, J. K. Nunes, A. Garnett, R. Biellik, D. Leboulleux, A. J. Birkett, C. Loucq,		
865		Aligning new interventions with developing country health systems: Target product		
866		profiles, presentation, and clinical trial design. Global Public Health 7, 931-945 (2012).		
867	3.	R. Chin, B. Y. Lee, Principles and practice of clinical trial medicine. (Elsevier, 2008).		
868	4.	J. N. Burrows, S. Duparc, W. E. Gutteridge, R. H. van Huijsduijnen, W. Kaszubska, F.		
869		Macintyre, S. Mazzuri, J. J. Möhrle, T. N. Wells, New developments in anti-malarial		
870		target candidate and product profiles. <i>Malaria journal</i> 16 , 26 (2017).		
871	5.	U. F. a. D. Administration., Guidance for industry and review staff Target Product Profile		
872		— a strategic development process tool. available at		
873		https://www.fda.gov/media/102657/download. (2007).		
874	6.	B. Y. Lee, D. S. Burke, Constructing target product profiles (TPPs) to help vaccines		
875		overcome post-approval obstacles. Vaccine 28, 2806-2809 (2010).		
876	7.	K. B. Ebels, C. Clerk, C. H. Crudder, S. McGray, K. Magnuson, K. Tietje, P. LaBarre, in		
877		IEEE Global Humanitarian Technology Conference (GHTC 2014). (IEEE, 2014), pp.		
878		555-560.		
879	8.	H. Heesterbeek, R. M. Anderson, V. Andreasen, S. Bansal, D. De Angelis, C. Dye, K. T.		
880		Eames, W. J. Edmunds, S. D. Frost, S. Funk, Modeling infectious disease dynamics in		
881		the complex landscape of global health. Science 347, (2015).		
882	9.	R. M. Anderson, B. Anderson, R. M. May, Infectious diseases of humans: dynamics and		
883		<i>control.</i> (Oxford university press, 1991).		
884	10.	M. A. Penny, R. Verity, C. A. Bever, C. Sauboin, K. Galactionova, S. Flasche, M. T.		
885		White, E. A. Wenger, N. Van de Velde, P. Pemberton-Ross, Public health impact and		
886		cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of		
887		predictions from four mathematical models. <i>The Lancet</i> 387 , 367-375 (2016).		
888	11.	H. C. Slater, A. Ross, A. L. Ouédraogo, L. J. White, C. Nguon, P. G. Walker, P. Ngor, R.		
889		Aguas, S. P. Silal, A. M. Dondorp, Assessing the impact of next-generation rapid		
890		diagnostic tests on Plasmodium falciparum malaria elimination strategies. <i>Nature</i> 528 ,		
891		S94-S101 (2015).		
892	12.	J. Gerardin, C. A. Bever, B. Hamainza, J. M. Miller, P. A. Eckhoff, E. A. Wenger,		
893	·	Optimal Population-Level Infection Detection Strategies for Malaria Control and		
075		optimit i spanaton Devel interior Detection bratefies for matural control and		

894		Elimination in a Spatial Model of Malaria Transmission. <i>PLOS Computational Biology</i>
895	10	12 , e1004707 (2016).
896	13.	M. Walker, J. I. Hamley, P. Milton, F. Monnot, B. Pedrique, MG. Basáñez, Designing
897		antifilarial drug trials using clinical trial simulators. <i>Nature Communications</i> 11 , 1-11
898	14	(2020).
899	14.	H. Kimko, J. Pinheiro, Model-based clinical drug development in the past, present and
900	15	future: a commentary. Br. J. Clin. Pharmacol. 79 , 108-116 (2015).
901	15.	C. Vegvari, E. Cauet, C. Hadjichrysanthou, E. Lawrence, GJ. Weverling, F. De Wolf,
902		R. M. Anderson, Using clinical trial simulators to analyse the sources of variance in $\frac{1}{2}$
903	16	clinical trials of novel therapies for acute viral infections. <i>PloS one</i> 11 , (2016).
904	16.	P. Selvaraj, J. Suresh, E. A. Wenger, C. A. Bever, J. Gerardin, Reducing malaria burden
905		and accelerating elimination with long-lasting systemic insecticides: a modelling study of three potential was pages. <i>Malaria journal</i> 18 , 207, 207 (2010)
906	17.	three potential use cases. <i>Malaria journal</i> 18 , 307-307 (2019).
907 908	17.	O. J. Brady, H. C. Slater, P. Pemberton-Ross, E. Wenger, R. J. Maude, A. C. Ghani, M. A. Penny, J. Gerardin, L. J. White, N. Chitnis, Role of mass drug administration in
908 909		elimination of Plasmodium falciparum malaria: a consensus modelling study. <i>The Lancet</i>
909 910		Global Health 5, e680-e687 (2017).
910 911	18.	M. Kretzschmar, Disease modeling for public health: added value, challenges, and
911 912	10.	institutional constraints. Journal of public health policy 41 , 39-51 (2020).
912 913	19.	K. Panayidou, S. Gsteiger, M. Egger, G. Kilcher, M. Carreras, O. Efthimiou, T. P.
913 914	1).	Debray, S. Trelle, N. Hummel, G. m. r. group, GetReal in mathematical modelling: a
91 4 915		review of studies predicting drug effectiveness in the real world. <i>Research synthesis</i>
915 916		methods 7, 264-277 (2016).
917	20.	L. Rychetnik, M. Frommer, P. Hawe, A. Shiell, Criteria for evaluating evidence on public
918	20.	health interventions. Journal of Epidemiology and Community Health 56, 119 (2002).
919	21.	A. B. Hogan, P. Winskill, R. Verity, J. T. Griffin, A. C. Ghani, Modelling population-
920		level impact to inform target product profiles for childhood malaria vaccines. <i>BMC</i>
921		<i>medicine</i> 16 , 1-11 (2018).
922	22.	G. F. Killeen, N. Chitnis, S. J. Moore, F. O. Okumu, Target product profile choices for
923		intra-domiciliary malaria vector control pesticide products: repel or kill? <i>Malaria journal</i>
924		10 , 207 (2011).
925	23.	W. Pan-Ngum, T. Kinyanjui, M. Kiti, S. Taylor, JF. Toussaint, S. Saralamba, T. Van
926		Effelterre, D. J. Nokes, L. J. White, Predicting the relative impacts of maternal and
927		neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus
928		modelling approach. <i>Vaccine</i> 35 , 403-409 (2017).
929	24.	C. E. Rasmussen, C. K. I. Williams, Gaussian Processes for Machine Learning (Adaptive
930		Computation and Machine Learning). (The MIT Press, 2005).
931	25.	D. Ríos Insua, F. Ruggeri, M. P. Wiper, Bayesian analysis of stochastic process models.
932		(Wiley, Chichester, 2012).
933	26.	WHO, World Health Organization: Global report on insecticide resistance in malaria
934		vectors: 2010–2016 accessed at
935		https://www.who.int/malaria/areas/vector control/insecticide resistance/en/. (2018).
936	27.	L. J. Espinoza, Malaria Resurgence in the Americas: An Underestimated Threat.
937		Pathogens 8, (2019).
938	28.	C. J. M. Whitty, E. Ansah, Malaria control stalls in high incidence areas. BMJ 365, 12216
939		(2019).

0.40	20	T. Smith N. Maira, A. Dass, M. Danny, N. Chitnis, A. Sahanira, A. Studar, D. Canton, C.
940 041	29.	T. Smith, N. Maire, A. Ross, M. Penny, N. Chitnis, A. Schapira, A. Studer, B. Genton, C. Lengeler, F. Tediosi, D. De Savigny, M. Tanner, Towards a comprehensive simulation
941 042		model of malaria epidemiology and control. <i>Parasitology</i> 135 , 1507-1516 (2008).
942 042	20	
943	30.	P. Winskill, P. G. T. Walker, J. T. Griffin, A. C. Ghani, Modelling the cost-effectiveness
944		of introducing the RTS, S malaria vaccine relative to scaling up other malaria
945		interventions in sub-Saharan Africa. <i>BMJ Global Health</i> 2 , e000090 (2017).
946	31.	P. Winskill, P. G. Walker, R. E. Cibulskis, A. C. Ghani, Prioritizing the scale-up of
947		interventions for malaria control and elimination. Malaria Journal 18, 122 (2019).
948	32.	E. Korenromp, G. Mahiané, M. Hamilton, C. Pretorius, R. Cibulskis, J. Lauer, T. A.
949		Smith, O. J. T. Briët, Malaria intervention scale-up in Africa: effectiveness predictions
950		for health programme planning tools, based on dynamic transmission modelling. Malaria
951		<i>Journal</i> 15 , 417 (2016).
952	33.	T. Smith, G. F. Killeen, N. Maire, A. Ross, L. Molineaux, F. Tediosi, G. Hutton, J.
953		Utzinger, K. Dietz, M. Tanner, Mathematical modeling of the impact of malaria vaccines
954		on the clinical epidemiology and natural history of Plasmodium falciparum malaria:
955		overview. The American Journal of Tropical Medicine and Hygiene 75, 1-10 (2006).
956	34.	E. Cameron, K. E. Battle, S. Bhatt, D. J. Weiss, D. Bisanzio, B. Mappin, U. Dalrymple,
957		S. I. Hay, D. L. Smith, J. T. Griffin, E. A. Wenger, P. A. Eckhoff, T. A. Smith, M. A.
958		Penny, P. W. Gething, Defining the relationship between infection prevalence and
959		clinical incidence of Plasmodium falciparum malaria. <i>Nature Communications</i> 6, 8170
960		(2015).
961	35.	C. E. Utazi, J. Thorley, V. A. Alegana, M. J. Ferrari, S. Takahashi, C. J. E. Metcalf, J.
962		Lessler, F. T. Cutts, A. J. Tatem, Mapping vaccination coverage to explore the effects of
963		delivery mechanisms and inform vaccination strategies. <i>Nature communications</i> 10 , 1-10
964		(2019).
965	36.	A. L. Wilson, O. Courtenay, L. A. Kelly-Hope, T. W. Scott, W. Takken, S. J. Torr, S. W.
966		Lindsay, The importance of vector control for the control and elimination of vector-borne
967		diseases. PLoS neglected tropical diseases 14, e0007831 (2020).
968	37.	N. M. Ferguson, Challenges and opportunities in controlling mosquito-borne infections.
969		Nature 559 , 490-497 (2018).
970	38.	J. Gutman, S. Kovacs, G. Dorsey, A. Stergachis, F. O. ter Kuile, Safety, tolerability, and
971	50.	efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and
972		treatment of malaria: a systematic review and meta-analysis. <i>The Lancet infectious</i>
973		diseases 17, 184-193 (2017).
974	39.	F. Macintyre, H. Ramachandruni, J. N. Burrows, R. Holm, A. Thomas, J. J. Möhrle, S.
975	57.	Duparc, R. H. van Huijsduijnen, B. Greenwood, W. E. Gutteridge, Injectable anti-
976		malarials revisited: discovery and development of new agents to protect against malaria.
970 977		Malaria journal 17, 402 (2018).
	40.	L. T. Wang, L. S. Pereira, Y. Flores-Garcia, J. O'Connor, B. J. Flynn, A. Schön, N. K.
978 070	40.	Hurlburt, M. Dillon, A. S. Yang, A. Fabra-García, A Potent Anti-Malarial Human
979 080		
980 081		Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes
981 082	41	Sporozoites in the Liver. Immunity 53, 733-744. e738 (2020).
982	41.	D. J. Weiss, T. C. Lucas, M. Nguyen, A. K. Nandi, D. Bisanzio, K. E. Battle, E.
983		Cameron, K. A. Twohig, D. A. Pfeffer, J. A. Rozier, Mapping the global prevalence,
984		incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal
985		modelling study. The Lancet 394 , 322-331 (2019).

986	42.	M. Sahu, F. Tediosi, A. M. Noor, J. J. Aponte, G. Fink, Health systems and global
987		progress towards malaria elimination, 2000–2016. Malaria journal 19, 1-12 (2020).
988	43.	R. Ristl, S. Urach, G. Rosenkranz, M. Posch, Methods for the analysis of multiple
989		endpoints in small populations: A review. Journal of biopharmaceutical statistics 29, 1-
990		29 (2019).
991	44.	Food, D. Administration, Multiple endpoints in clinical trials: guidance for industry.
992		College Park, Maryland: Food and Drug Administration, (2017).
993	45.	T. Smith, A. Ross, N. Maire, N. Chitnis, A. Studer, D. Hardy, A. Brooks, M. Penny, M.
994		Tanner, Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic
995		Malaria Vaccine. PLOS Medicine 9, e1001157 (2012).
996	46.	N. Chitnis, T. Smith, R. Steketee, A mathematical model for the dynamics of malaria in
997		mosquitoes feeding on a heterogeneous host population. Journal of Biological Dynamics
998		2, 259-285 (2008).
999	47.	N. Chitnis, D. Hardy, T. Smith, A Periodically-Forced Mathematical Model for the
1000		Seasonal Dynamics of Malaria in Mosquitoes. Bulletin of Mathematical Biology 74,
1001		1098-1124 (2012).
1002	48.	N. Maire, T. Smith, A. Ross, S. Owusu-Agyei, K. Dietz, L. Molineaux, A model for
1003		natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic
1004		areas. The American journal of tropical medicine and hygiene 75, 19-31 (2006).
1005	49.	A. Ross, G. Killeen, T. Smith, Relationships between host infectivity to mosquitoes and
1006		asexual parasite density in Plasmodium falciparum. The American journal of tropical
1007		<i>medicine and hygiene</i> 75 , 32-37 (2006).
1008	50.	A. Ross, N. Maire, L. Molineaux, T. Smith, An epidemiologic model of severe morbidity
1009		and mortality caused by Plasmodium falciparum. The American journal of tropical
1010		<i>medicine and hygiene</i> 75 , 63-73 (2006).
1011	51.	T. Smith, A. Ross, N. Maire, C. Rogier, JF. Trape, L. Molineaux, An epidemiologic
1012		model of the incidence of acute illness in Plasmodium falciparum malaria. The American
1013		journal of tropical medicine and hygiene 75 , 56-62 (2006).
1014	52.	F. Tediosi, N. Maire, T. Smith, G. Hutton, J. Utzinger, A. Ross, M. Tanner, An approach
1015		to model the costs and effects of case management of plasmodium falciparum malaria in
1016		sub-saharan Africa. The American Journal of Tropical Medicine and Hygiene 75, 90-103
1017		(2006).
1018	53.	M. A. Penny, N. Maire, C. A. Bever, P. Pemberton-Ross, O. J. T. Briët, D. L. Smith, P.
1019		W. Gething, T. A. Smith, Distribution of malaria exposure in endemic countries in Africa
1020		considering country levels of effective treatment. Malaria Journal 14, 384 (2015).
1021	54.	N. R. Smith, J. M. Trauer, M. Gambhir, J. S. Richards, R. J. Maude, J. M. Keith, J. A.
1022		Flegg, Agent-based models of malaria transmission: a systematic review. Malaria journal
1023		17, 1-16 (2018).
1024	55.	T. Reiker, N. Chitnis, T. A. Smith, Modelling reactive case detection strategies for
1025		interrupting transmission of Plasmodium falciparum malaria. Malaria Journal 18, 259
1026		(2019).
1027	56.	N. Maire, F. Tediosi, A. Ross, T. Smith, Predictions of the epidemiologic impact of
1028		introducing a pre-erythrocytic vaccine into the expanded program on immunization in
1029		sub-Saharan Africa. The American Journal of Tropical Medicine and Hygiene 75, 111-
1030		118 (2006).

1031 57. A. M. Ekström, J. Clark, P. Byass, A. Lopez, D. De Savigny, C. A. Mover, H. Campbell, 1032 A. J. Gage, P. Bocquier, C. AbouZahr, O. Sankoh, INDEPTH Network: contributing to the data revolution. The Lancet Diabetes & Endocrinology 4, 97 (2016). 1033 1034 58. G. F. Kileen, A. Ross, T. Smith, Infectiousness of malaria-endemic human populations to vectors. The American Journal of Tropical Medicine and Hygiene 75, 38-45 (2006). 1035 1036 59. T. C. Smith, J. D. D. Charlwood, J. Kihonda, S. Mwankusye, P. F. Billingsley, J. Meuwissen, E. B. Lyimo, W. Takken, T. Teuscher, M. Tanner, Absence of seasonal 1037 1038 variation in malaria parasitaemia in an area of intense seasonal transmission. Acta tropica 1039 **54 1**, 55-72 (1993). 1040 60. C. Drakeley, D. Schellenberg, J. Kihonda, C. Sousa, A. Arez, D. Lopes, J. Lines, H. Mshinda, C. Lengeler, J. A. Schellenberg, An estimation of the entomological inoculation 1041 1042 rate for Ifakara: a semi-urban area in a region of intense malaria transmission in Tanzania. Tropical Medicine & International Health 8, 767-774 (2003). 1043 1044 61. A. M. Shaukat, J. G. Breman, F. E. McKenzie, Using the entomological inoculation rate 1045 to assess the impact of vector control on malaria parasite transmission and elimination. Malaria journal 9, 122 (2010). 1046 62. L. S. Tusting, T. Bousema, D. L. Smith, C. Drakeley, in Advances in parasitology. 1047 (Elsevier, 2014), vol. 84, pp. 151-208. 1048 1049 M. Stein, Large Sample Properties of Simulations Using Latin Hypercube Sampling. 63. 1050 Technometrics 29, 143-151 (1987). M. Binois, R. B. Gramacy, M. Ludkovski, Practical heteroscedastic gaussian process 1051 64. modeling for large simulation experiments. Journal of Computational and Graphical 1052 Statistics 27, 808-821 (2018). 1053 M. Binois, R. Gramacy, hetGP: Heteroskedastic Gaussian Process Modeling and Design 1054 65. 1055 under Replication. *R package version* **1**, (2017). A. M. Gopakumar, P. V. Balachandran, D. Xue, J. E. Gubernatis, T. Lookman, Multi-1056 66. 1057 objective optimization for materials discovery via adaptive design. Scientific reports 8, 3738 (2018). 1058 R. Dehghannasiri, D. Xue, P. V. Balachandran, M. R. Yousefi, L. A. Dalton, T. 1059 67. 1060 Lookman, E. R. Dougherty, Optimal experimental design for materials discovery. Computational Materials Science 129, 311-322 (2017). 1061 M. Binois, J. Huang, R. B. Gramacy, M. Ludkovski, Replication or Exploration? 1062 68. 1063 Sequential Design for Stochastic Simulation Experiments. *Technometrics* 61, 7-23 (2019). 1064 69. I. M. Sobol', Global sensitivity indices for nonlinear mathematical models and their 1065 1066 Monte Carlo estimates. *Mathematics and Computers in Simulation* **55**, 271-280 (2001). 1067 70. A. Saltelli, S. Tarantola, F. Campolongo, M. Ratto, Sensitivity Analysis in Practice: A Guide to Assessing Scientific Models. (Halsted Press, 2004). 1068 1069 71. R. C. Team. (Vienna, Austria, 2013). M. R. Hestenes, Multiplier and gradient methods. Journal of Optimization Theory and 1070 72. 1071 Applications 4, 303-320 (1969). 1072 73. Y. Ye, Ph. D. thesis, Department of ESS, Stanford University, (1987). 1073 74. A. Ghalanos, S. Theussl, Rsolnp: general non-linear optimization using augmented Lagrange multiplier method. *R package version* **1**, (2012). 1074 T. Smith, N. Maire, K. Dietz, G. F. Killeen, P. Vounatsou, L. Molineaux, M. Tanner, 1075 75. Relationship between the entomologica inoculation rate and the force of infection for 1076

1077 1078 1079 1080	76.	 Plasmodium Falciparum malaria. <i>The American Journal of Tropical Medicine and Hygiene</i> 75, 11-18 (2006). W. E. Collins, G. M. Jeffery, A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum. <i>The American journal of</i>
1080		tropical medicine and hygiene 61 , 44-48 (1999).
1082	77.	G. F. Killeen, A. Ross, T. Smith, Infectiousness of malaria-endemic human populations
1083		to vectors. The American journal of tropical medicine and hygiene 75, 38-45 (2006).
1084	78.	A. Ross, T. Smith, The effect of malaria transmission intensity on neonatal mortality in
1085		endemic areas. The American journal of tropical medicine and hygiene 75, 74-81 (2006).
1086	79.	E. M. Stuckey, T. Smith, N. Chitnis, Seasonally Dependent Relationships between
1087		Indicators of Malaria Transmission and Disease Provided by Mathematical Model
1088		Simulations. PLOS Computational Biology 10, e1003812 (2014).
1089		
1090		
1091		

Supplementary Materials: 1092

Title: Combining machine learning and mathematical models of disease 1093 dynamics to guide development of novel disease interventions 1094

- Authors: Monica Golumbeanu^{1,2}[†], Guojing Yang^{1,2}[†], Flavia Camponovo^{1,2,3}, Erin M. Stuckey⁴, Nicholas Hamon⁵, Mathias Mondy⁵, Sarah Rees⁵, Nakul Chitnis^{1,2}, Ewan Cameron^{6,7,8}, and 1095 1096 Melissa A. Pennv^{1,2}*
- 1097

1098 **Affiliations:**

- ¹Swiss Tropical and Public Health Institute, Basel, Switzerland 1099
- ²University of Basel, Basel, Switzerland 1100
- 1101 ³Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H.
- Chan School of Public Health, Boston, MA 02115, USA 1102
- ⁴The Bill and Melinda Gates Foundation, Seattle, WA, USA 1103
- 1104 ⁵Innovative Vector Control Consortium, Liverpool, United Kingdom
- ⁶Malaria Atlas Project, Big Data Institute, University of Oxford, Oxford, UK 1105
- ⁷Curtin University, Perth, Australia 1106
- ⁸Telethon Kids Institute, Perth Children's Hospital, Perth, Australia 1107
- 1108 *Correspondence to: melissa.penny@unibas.ch
- [†]These authors contributed equally. 1109
- One Sentence Summary: Defining quantitative profiles of novel disease interventions by 1110
- combining machine learning with mathematical models of disease transmission 1111
- Short title: Ouantitatively defining new disease interventions 1112
- 1113
- **Supplementary Materials:** 1114
- 1115

Table of contents 1116

1117	1 Disease model	41
1118	Table S1.1 Overview of the OpenMalaria model components.	42
1119	2 Disease scenarios	43
1120	Figure S2.1 Illustration of the yearly malaria transmission and prevalence patterns in simulated	t
1121	seasonal settings.	43
1122	Figure S2.2 Simulated distributions of true and patent (detected with PCR or RDT) PfPR ₀₋₉₉ ar	ıd
1123	<i>Pf</i> PR ₂₋₁₀ for various input EIR levels in absence of interventions	45
1124	Figure S2.3 Representation of decay and the range of efficacy and half-life against different	
1125	parasite or vector targets for intervention-agnostic malaria interventions	46
1126	Table S2.1 Description and ranges of simulation variables.	47
1127	Table S2.2 Specifications of the optimization procedure for TPP development	48
1128	3 Results: Disease model simulations	50
1129	Figure S3.1. Examples of OpenMalaria simulation outputs.	50
1130	Figure S3.2. Distributions of prevalence reduction following yearly deployment of single	
1131	interventions	51
1132	Figure S3.3. Distributions of prevalence reduction following yearly deployment of combination	ns
1133	of interventions	52

1134	Figure S3.4. Distributions of prevalence reduction following deployment of single and
1135	combinations of interventions twice per year
1136	Figure S3.5. Simulations reaching malaria elimination before intervention deployment
1137	4 Results: Emulator performance
1138	Figure S4.1. Assessment of the performance of the trained GP depending on the training set
1139	size55
1140	Figure S4.2. Performance of the trained GP emulators predicting immediate intervention impact.
1141	
1142	Figure S4.3. Performance of the trained GP emulators predicting long-term intervention impact.
1143	
1144	Table S4.1. Performance of the trained GP emulators predicting immediate and long-term
1145	intervention impact
1146	5 Results: Summary of key intervention impact determinants, optimal intervention profiles, and
1147	vaccine results
1148	Table S5.1. Key findings guiding target product profiles of new malaria interventions60
1149	6 Results: Key determinants of impact
1150	Figure S6.1. Key drivers of impact for therapeutic malaria interventions across different
1150	transmission settings
1152	Figure S6.2. Key drivers of impact for vector control malaria interventions across different
1152	transmission settings
1155	7 Results: Feasible landscapes of optimal, constrained intervention profiles
1154	Figure S7.1. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-
1155	infective monoclonal antibody deployed once per year
1150	Figure S7.2. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-
1157	infective monoclonal antibody deployed twice per year
1158	Figure S7.3 Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-
1160	infective vaccine deployed once per year
1161	Figure S7.4. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for a
1162	transmission-blocking vaccine deployed once per year
1162	Figure S7.5. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for
1165	attractive targeted sugar baits deployed once or twice per year
1164	Figure S7.6. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for eave
	tubes deployed once per year
1166	8 Results: Optimal intervention profiles
1167	1 1
1168	Figure S8.1 Optimal intervention profiles (TPPs) for anti-infective monoclonal antibodies under
1169	various deployment regimes to achieve a $P_f PR_{0.99}$ reduction of at least 70%
1170	Figure S8.2 Optimal intervention profiles (TPPs) for anti-infective vaccines under various
1171	deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%
1172	Figure S8.3 Optimal intervention profiles (TPPs) for transmission-blocking vaccines under
1173	various deployment regimes to achieve a $P_f PR_{0.99}$ reduction of at least 70%
1174	Figure S8.4 Optimal intervention profiles (TPPs) for attractive targeted sugar baits under various
1175	deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%
1176	Figure S8.5 Optimal intervention profiles (TPPs) for eave tubes to achieve a $PfPR_{0-99}$ reduction
1177	of at least 70%75
1178	
1179	

1180 **1 Disease model**

1181

Name	Description and assumptions	References
Key modelled epidemi	ological processes	
Malaria infection of humans	 Determined by EIR which is a model input and affects the force of infection in the simulated setting Exposure of humans to mosquitoes depends on age 	(33, 75)
Infection progression in humans: asexual parasite densities and immunity	 Blood stage parasite density depends on the time since infection and is affected by naturally acquired immunity The duration of infection follows a log-normal distribution Immunity (both pre-erythrocytic and blood-stage) develops progressively following consequent episodes of exposure to infection and decays exponentially Acquired immunity reduces parasite density of subsequent infections Super-infection is possible with cumulative parasite densities 	(<i>33, 48, 75,</i> 76)
Transmission from infected humans to mosquitoes	- Depends on the density of parasites present in the human with gametocyte densities following a lag from parasite densities	(33, 49, 77)
Clinical illness, morbidity, mortality and anemia	 Acute clinical illness depends on human host parasite densities and their pyrogenic threshold which evolves over time depending on the individual exposure history Acute morbidity episodes can be uncomplicated or evolve to severe episodes A proposition of the severe episodes leads to deaths 	(33, 50, 51, 78)
Modelled characteristi	cs of the transmission setting	
Population age structure	- Informed by health and demographic surveillance data from Tanzania	(50, 57)
Transmission seasonality	- Seasonally-forced, the same transmission pattern is reproduced each year in absence of interventions	(75, 79)
Case management	 Modelled through a comprehensive decision tree-based model which determines the corresponding treatment implications depending on the occurring clinical events such as fevers and seeking of care Its representation includes specification of diagnostic tests, effects of treatment, case fatality, case sequelae and cure rates 	(52)
Entomological setting	 Comprehensive simulation of the mosquito lifecycle and behavior towards human and animal hosts (biting, resting) embedded in a dynamic entomological model of the mosquito oviposition cycle Multiple vector species can be simulated simultaneously 	(47)

Modelled interventions						
- Vector control	Available interventions: long-lasting insecticide-treated nets (LLINs), indoor residual spraying (IRS), house screening, baited traps, repellents, push-pull					
- Drugs and Vaccines	Drugs and vaccines acting at various levels of the parasite life cycle (transmission blocking, anti-infective, blood-stage clearance)					
Deployment - characteristics	Interventions can be deployed for several rounds to a targeted group of individuals and specified coverages					
Simulation regimes and n	nodel variants					
Time steps -	Simulation outputs are tracked every 5 days					
- Model variants	Varying assumptions in immunity decay, treatment and (45) heterogeneity of transmission result in 14 model variants					
Software availability and documentation						
- Source code and wiki page available on GitHub: <u>https://github.com/SwissTPH/openmalaria/</u>						

1183

1184 **Table S1.1**

1185 **Overview of the OpenMalaria model components.**

1186 The individual based stochastic model of malaria in humans and transmission has been described

previously. This model was originally developed in 2003-2006 (*33*), with mosquito dynamics


updated in 2008 (46) and an additional 13 structural model variants developed and parameterized

1189 in 2012 (45) representing different model assumptions on immunity decay, disease,

1190 comorbidities, and heterogeneity in transmission.

1192 **2 Disease scenarios**






1194

1195 Figure S2.1

1196 Illustration of the yearly malaria transmission and prevalence patterns in simulated 1197 seasonal settings.

1198 (A) Observed, normalized, monthly seasonal pattern of malaria EIR in Namawala, Tanzania extracted from (50). (B) Corresponding input, 5-day seasonal EIR pattern used in OpenMalaria 1199 simulations, obtained by scaling and extrapolating the monthly seasonality profile from (50) to 5-1200 day time steps. For this example, the simulated input EIR was 7.78 infectious bites per person 1201 per year. (C) Resulting simulated yearly $PfPR_{0-99}$ profile. In all figures, the arrows indicate the 1202 month of September, the peak of transmission and show the delay between the peak of 1203 transmission and the resulting peak in malaria prevalence. The dotted vertical lines on figures 1204 1205 (B) and (C) indicate the deployment times of first and second rounds of malaria interventions when applicable. 1206




1209 Figure S2.2

1210 Simulated distributions of true and patent (detected with PCR or RDT) *Pf*PR₀₋₉₉ and

1211 *Pf*PR₂₋₁₀ for various input EIR levels in absence of interventions.

The input entomological inoculation rate (EIR) defines the simulated malaria transmission level. 1212 1213 In every simulation experiment, EIR was uniformly sampled from the interval [1, 25]. In figures (A) - (C), each panel corresponds to a simulated setting and presents the distributions of true 1214 (A), patent with PCR (B) and patent with RDT (C) Plasmodium falciparum prevalence (PfPR, 1215 shown with boxplots, blue for 0-99 years old and orange for 2-10 years old) at varying EIR 1216 levels (x axis). The 6 represented settings are defined by the seasonality pattern (perennial shown 1217 1218 in the first row, or seasonal shown in the second row of each figure) and mosquito indoor biting behavior (low- shown in the first column, mid- shown in the second column or high-indoor 1219 biting shown in the third column of each figure). Each EIR level on the x axis is defined as a set 1220 1221 of continuous input EIR values which range between the current level and the current level - 1, e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. For each EIR level and 1222 setting, the case management levels, i.e., the probability of seeking care (access to treatment) 1223 1224 within 5 days from the onset of fever (E_5), was varied within the interval [0.04 - 0.5]. PCR stands for polymerase chain reaction and RDT stands for rapid diagnostic test. 1225 1226



1227

1228 Figure S2.3

Representation of decay and the range of efficacy and half-life against different parasite or vector targets for intervention-agnostic malaria interventions.

1231 The simulated malaria interventions $(\mathbf{A} - \mathbf{F})$ were modeled in terms of their targets in the malaria transmission cycle. The effect of each intervention is represented through the half-life of its 1232 decay (x axis) as well as the initial efficacy (y axis). The color blocks represent the range of 1233 parameter space of efficacy and half-life of decay considered in the current analysis for each 1234 intervention. The half-life and the color block does not represent the entire duration of effect, as 1235 that depends on the decay shape chosen for each intervention. The decay shape for each 1236 intervention is displayed in the right side insert of each plot where the dotted lines specify the 1237 half-life and corresponding half of the intervention efficacy. The definitions of all the parameter 1238 ranges for all interventions are provided in each figure on the lower left side and detailed in 1239 1240 Table S2.1.

	Intervention	Coverage	Initial efficacy	Half-life or duration (years)	Decay type		
	Prevent infection						
	Anti-infective vaccine	0 - 1	0.3 - 0.95	0.5 - 5	Weibull (k = 0.8) (Sigmoidal)		
	Anti-infective monoclonal antibody	0 - 1	0.3 - 0.95	0.167 - 0.667	Weibull (k = 3) (Biphasic)		
	Blood stage clearance	<u>e</u>					
Intervention profiles	Antimalarial drugs	0 - 1	0.8 - 1	0 - 0.1667	Exponential		
-	Transmission blockir	Ig					
	Vaccine	0 - 1	0.3 - 0.95	0.5 - 5	Weibull (k = 0.8) (Biphasic)		
	Preprandial killing effect (affects only indoor mosquito biting)						
	Eave tubes	0 - 1	0.3 - 0.99	0.5 - 5	Weibull (k = 3) (Sigmoidal)		
	Preprandial and postprandial killing effect (affects indoor and outdoor mosquito biting)						
	Attractive targeted sugar baits	0 -1	0.7 - 0.99	0.167 – 0.667	Step		
Transmission	EIR range: 1 – 25, representing a $PfPR_{0.99}$ of 13-88% and a $PfPR_{0.2}$ of 7.2-74% Case management (baseline scenario) range: 0 – 0.8, corresponding to a probability of seeking care within 5 days from the onset of fever of 0-0.5 Seasonality levels:						
settings	 high seasonal setting with one transmission peak over a year perennial setting with constant yearly transmission Proportion of indoor-biting mosquitoes, out of total indoor and outdoor biting mosquitoes: high (0.8) medium (0.5) low (0.2) 						

1242 **Table S2.1 Description and ranges of simulation variables**.

Within each OpenMalaria simulation, the varied parameters and ranges correspond to the 1243 profiles of applied interventions (see Fig S2.3 for visual ranges of vector and parasite targets), as 1244 well as the transmission setting characteristics. The profile of each modeled malaria intervention 1245 is defined by its target, the ranges of the deployment coverage, initial efficacy, half-life or 1246 1247 duration of effect as well the type of decay. Where interventions are applied to individual humans, in the present demonstrative analysis this is equally applied across ages, and not 1248 targeted to certain population. The transmission setting is defined by the yearly EIR, seasonality 1249 level, as well as proportion of indoor mosquitoes. 1250

Intervention	Minimized profile	Intervention properties constraints	Specifications of combination therapies
	Coverage	Coverage $\in [0 80\%]$ Efficacy = 85% Half-life = 4 months	
Anti-infective monoclonal antibody (Sigmoidal decay)	Efficacy	Coverage = 60% Efficacy $\in [30\% 95\%]$ Half-life = 4 months	$\frac{Blood stage drug:}{Efficacy = 90\%}$ Half-life = 10 days
	Half-life	Coverage = 60% Efficacy = 85% Half-life $\in [2 8 months]$	
	Coverage	Coverage $\in [0 80\%]$ Efficacy = 85% Half-life = 7 months	
Anti-infective vaccine (Biphasic decay)	Efficacy	Coverage = 60% Efficacy $\in [30\% 95\%]$ Half-life = 7 months	Blood stage drug: Efficacy = 90% Half-life = 10 days
	Half-life	Coverage = 60% Efficacy = 85% Half-life $\in [2 \text{ months 5 years}]$	
	Coverage	Coverage \in [0 80%] Efficacy = 85% Half-life = 7 months	
Transmission- blocking vaccine (Biphasic decay)	Efficacy	Coverage = 60% Efficacy $\in [30\% 95\%]$ Half-life = 7 months	Blood stage drug: Efficacy = 90% Half-life = 10 days
	Half-life	Coverage = 60% Efficacy = 85% Half-life $\in [2 \text{ months 5 years}]$	
	Coverage	Coverage \in [0 80%] Efficacy = 85% Half-life = 4 months	
Attractive targeted sugar baits (Step decay)	Efficacy	Coverage = 60% Efficacy \in [70% 99%] Half-life = 4 months	Not applicable
(200)	Half-life	Coverage = 60% Efficacy = 85% Half-life $\in [2 8 months]$	
	Coverage	Coverage \in [0 80%] Efficacy = 85% Half-life = 3 years	
Eave tubes (Sigmoidal decay)	Efficacy	Coverage = 60% Efficacy $\in [30\% 99\%]$ Half-life = 3 years	Not applicable
	Half-life	Coverage = 60% Efficacy = 85% Half-life $\in [6 \text{ months 5 years}]$	

1251 **Table S2.2**

1252 Specifications of the optimization procedure for TPP development.

For each intervention, we successively identified the minimum profiles of the intervention coverage, efficacy, and half-life. Precisely, we optimized each parameter separately (column "Minimized profile"), according to its feasibility constraints while setting the two other

1256 parameters to the specified fixed values (column "Intervention properties constraints"). When

deployed in combination with other drugs or vaccines, the additional interventions had fixed

1258 properties as well (column "Specifications of combination therapies").

1.00 Α reference immediate late follow-up follow-up year 0.75 PfPR₀₋₉₉ 0.50 0.25 Applied interventions 0.00 0 2 4 5 6 8 9 10 11 13 15 Anti-infective monoclonal Time (years) Anti-infective vaccine 1.00 В Transmission-blocking vaccine reference immediate late Attractive targeted sugar baits year follow-up follow-up 0.75 *Pf*PR₀₋₉₉ Eave tubes 0.50 0.25 0.00 2 4 9 10 11 13 5 6 7 8 15 Time (years)

3 Results: Disease model simulations 1260

1261


Figure S3.1. 1263

Examples of OpenMalaria simulation outputs. 1264

Time series of simulated malaria $P_{f}PR_{0.99}$ in a perennial (A) and seasonal (B) setting. Both 1265 figures display the prevalence of malaria cases, PfPR₀₋₉₉, (y axis) across time (x axis). 1266 Interventions targeting different stages in the malaria transmission cycle (different colors) are 1267 applied once per year at the beginning of June (vertical dotted lines, in this example for three 1268 years of deployment). The effect of each intervention is assessed by evaluating the $PfPR_{0.99}$ 1269 reduction in all ages relative to the year prior deployment (first grey block). Two outcomes are 1270 assessed, following an immediate and late follow-up (second and third grey blocks), depending 1271 on whether the average prevalence is calculated across the next year after deployment, or across 1272 the third year after deployment, respectively. 1273

1274

1275




1276

1277 Figure S3.2.

1278 Distributions of prevalence reduction following yearly deployment of single interventions.

Prevalence reduction was calculated by comparing the initial prevalence in the year before any 1279 interventions were deployed to the yearly prevalence obtained in the following year (short 1280 follow-up, panel A) and in the third year (long follow-up, panel B) after deployment of 1281 interventions. Each individual figure corresponds to a simulated setting and presents the 1282 distributions of $PfPR_{0.99}$ reduction (shown with boxplots) at varying EIR as well as 1283 corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range 1284 1285 (box), the median value (horizontal line), the largest and smallest values within 1.5 times the interquartile range (whiskers), and the remaining outside values (points). The 6 represented 1286 1287 settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined 1288 as a set of continuous input EIR values which range between the current level and the current 1289 level - 1, e.g., an input EIR level of 1 contains all EIR values in the interval (0, 1]. The 1290 1291 definitions and ranges of all the EIR levels is included in Table S2.1.




1292

1293 **Figure S3.3.**

Distributions of prevalence reduction following yearly deployment of combinations of interventions.

Prevalence reduction was calculated by comparing the initial prevalence in the year before any 1296 interventions were deployed to the yearly prevalence obtained in the following year (short 1297 follow-up, panel A) and in the third year (long follow-up, panel B) after deployment of 1298 1299 interventions. Each individual figure corresponds to a simulated setting and presents the 1300 distributions of $PfPR_{0.99}$ reduction (shown with boxplots) at varying EIR as well as the corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range 1301 (box), the median value (horizontal line), the largest and smallest values within 1.5 times the 1302 interquartile range (whiskers), and the remaining outside values (points). The 6 represented 1303 settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito 1304 indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined 1305 as a set of continuous input EIR values which range between the current level and the current 1306 1307 level - 1, e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. The definitions

1308 and ranges of all the EIR levels are included in Table S2.1. MDA stands for mass drug 1309 administration.



1310

1311 **Figure S3.4**.


1312 Distributions of prevalence reduction following deployment of single and combinations of

1313 interventions twice per year.

Prevalence reduction was calculated by comparing the initial prevalence in the year before any 1314 interventions were deployed to the yearly prevalence obtained in the following year (short 1315 follow-up, panel A) and in the third year (long follow-up, panel B) after deployment of 1316 interventions. Each individual figure corresponds to a simulated setting and presents the 1317 distributions of PfPR₀₋₉₉ reduction (shown with boxplots) at varying EIR as well as 1318 corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range 1319 (box), the median value (horizontal line), the largest and smallest values within 1.5 times the 1320 interquartile range (whiskers), and the remaining outside values (points). The 6 represented 1321 settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito 1322 indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined 1323 as a set of continuous input EIR values which range between the current level and the current 1324

level - 1, e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. The definitions
and ranges of all the EIR levels for all simulated settings is included in Table S2.1. MDA stands

1327 for mass drug administration.




1328

1329 Figure S3.5.

1330 Simulations reaching malaria elimination before intervention deployment.

1331 The violin plots and boxplots in each panel present the distributions of the percentage of 1332 simulations reaching malaria elimination ($PfPR_{0.99} = 0$) before intervention deployment (this can 1333 arrive due to case management and only occurs in seasonal settings), across all simulated 1334 interventions and intervention combinations.




1338 1339

Figure S4.1. 1340


Assessment of the performance of the trained GP depending on the training set size. 1341

Each figure presents the Pearson correlation coefficient r^2 between true and predicted values on a 1342 broad range of out-of-sample test sets of varying length, when simulating deployment of an anti-1343 infective monoclonal antibody deployed once per year (A) or twice per year (B) as well as in 1344 combination with a blood-stage drug once (C) or twice per year (D). 1345




1347

1348 **Figure S4.2.**



For a wide range of deployed interventions and transmission settings (see Materials and 1350 Methods), GP emulators were trained to predict the immediate impact of each intervention, i.e., 1351 the resulting average $PfPR_{0.99}$ reduction in the year following deployment of the intervention. 1352 1353 The performance of the trained emulators was assessed by inspecting the Pearson correlation coefficient (r^2) and the mean squared error between true and predicted values on an out-of-1354 1355 sample test set. Figures (A) - (K) display the true and predicted values of each trained emulator across all deployed interventions in a seasonal transmission setting with high indoor biting. 1356 Figure (L) summarizes r^2 and the mean squared error of all the trained emulators for all 1357 simulated transmission settings and interventions (the simulated settings were defined by 1358 seasonality and mosquito biting patterns, see Table S2.1 for detailed values per setting). 1359



1360

1361 **Figure S4.3.**



For a wide range of deployed interventions and transmission settings (see Methods), GP 1363 emulators were trained to predict the immediate impact of each intervention, i.e., the resulting 1364 average PfPR₀₋₉₉ reduction in the third year following deployment of the intervention. The 1365 performance of the trained emulators was assessed by inspecting the Pearson correlation 1366 coefficient (r^2) and the mean squared error between true and predicted values on an out-of-1367 1368 sample test set. Figures (A) - (K) display the true and predicted values of each trained emulator across all deployed interventions in a seasonal transmission setting with high indoor biting. 1369 Figure (L) summarizes r^2 and the mean squared error of all the trained emulators for all 1370 simulated transmission settings and interventions (the simulated settings were defined by 1371 seasonality and mosquito biting patterns, see Table S2.1 for detailed values per setting). 1372

Intervention(s) (deployment)	Training set size	Test set size	Cross-validation r ² and (mean error)	Test set r ² and (mean error)
Anti-infective monoclonal antibody (once/year)	10000	5000	Immediate: 0.99 (1.02%) Long: 0.96 (1.15%)	Immediate: 0.99 (0.63%) Long: 0.97 (0.68%)
Anti-infective monoclonal antibody (twice/year)	5000	2500	Immediate: 0.99 (1.11%) Long: 0.97 (1.32%)	Immediate: 0.99 (0.91%) Long: 0.99 (0.83%)
Anti-infective monoclonal antibody + Blood stage drug (once/year)	10000	5000	Immediate: 0.99 (1.34%) Long: 0.96 (1.74%)	Immediate: 0.99 (1.18%) Long: 0.98 (1.05%)
Anti-infective monoclonal antibody + Blood stage drug (twice/year)	5000	2500	Immediate: 0.99 (1.26%) Long: 0.97 (1.98%)	Immediate: 0.99 (0.98%) Long: 0.99 (1.12%)
Anti-infective vaccine (once/year)	10000	5000	Immediate: 0.99 (1.08%) Long: 0.99 (1.3%)	Immediate: 0.99 (0.99%) Long: 0.99 (1.16%)
Anti-infective vaccine + Blood stage drug (once/year)	5000	2500	Immediate: 0.99 (1.18%) Long: 0.99 (1.63%)	Immediate: 0.99 (1.57%) Long: 0.99 (2.25%)
Transmission-blocking vaccine (once/year)	10000	5000	Immediate: 0.99 (1.13) Long: 0.99 (1.25%)	Immediate: 0.99 (0.89%) Long: 0.99 (1.07%)
Transmission-blocking vaccine + Blood stage drug (once/year)	5000	2500	Immediate: 0.99 (1.25%) Long: 0.99 (1.53%)	Immediate: 0.99 (1.68%) Long: 0.99 (2.23 %)
Attractive targeted sugar baits (once/year)	5000	2500	Immediate: 0.99 (1.26%) Long: 0.98 (1.71%)	Immediate: 0.99 (1.98%) Long: 0.99 (1.19%)
Attractive targeted sugar baits (twice/year)	5000	2500	Immediate: 0.99 (1.09%) Long: 0.99 (1.98%)	Immediate: 0.99 (1.03%) Long: 0.99 (1.29%)
Eave tubes (once/year)	10000	5000	Immediate: 0.99 (1.11%) Long: 0.99 (1.3%)	Immediate: 0.99 (0.89%) Long: 0.99 (1.26%)

1373 **Table S4.1.**

Performance of the trained GP emulators predicting immediate and long-term intervention impact.

For each modelled transmission setting defined by case management level and mosquito biting 1376 patterns and for each intervention (Table S2.1), a comprehensive set of simulation scenarios was 1377 built by sampling uniformly the parameter space (defined in Table S2.1) and simulation with 1378 1379 OpenMalaria. In this manner, a training and a test set were constructed. The training set was used to train, for each setting and intervention, a Heteroskedastic GP model in a 5-fold cross-1380 validation procedure. The performance of the trained GP was assessed by computing the Pearson 1381 correlation coefficient r^2 as well as the mean error between the true and predicted outcomes on 1382 both out-of-sample cross-validation and test sets. For each intervention and follow-up 1383 (immediate or long-term), the average r^2 and mean error for all the GP models trained across 6 1384 1385 settings (seasonal or perennial, high, medium or low mosquito indoor biting) are reported.

1386 **5 Results: Summary of key intervention impact determinants, optimal intervention**

1387 profiles, and vaccine results

	Intervention	Summary of analysis results	Relevant figures
_	Therapeutic interventions Anti-infective monoclonal antibodies Anti-infective vaccines Transmission- blocking vaccines	 Key determinants of impact The main driver of intervention impact was coverage The second determinant of intervention impact depended on intervention half-life. For interventions with short half-lives such as monoclonal antibodies, the half-life was the second driver, while for long-term interventions such as vaccines, efficacy played a key role. As opposed to long-term vaccines whose impact is mainly driven by coverage and efficacy, interventions with short half-life (e.g., anti-infective monoclonal antibodies) rely on the case management to prevent resurgence The various biting patterns of mosquitoes did not influence the intervention determinants of impact Optimal intervention profiles As opposed to vaccines, anti-infective monoclonal antibodies require high efficacy and deployment coverage while achieving limited reduction in <i>Pf</i>PR₀₋₉₉ with very little impact in perennial settings Increasing the deployment frequency for anti-infective monoclonal antibodies from once to twice per year, 	S6.1 and Figure 2 S7.1-S7.4
		 extended the landscape of feasible health targets but mainly in seasonal settings Combination with a blood-stage drug proved more impactful as compared to increasing the deployment frequency for anti-infective monoclonal antibodies, extending the achievable health goals in perennial settings as well 	S8.1-S8.3 and Figure 3
_	Vector control interventions Attractive targeted sugar baits Eave tubes	 Key determinants of impact As with short-term therapeutic interventions such as anti-infective monoclonal antibodies, attractive targeted sugar baits rely on case management for preventing resurgence We see limited difference between key drivers for attractive targeted sugar baits in different biting settings because mosquitoes sugar feed before indoor or outdoor biting. In contrast, we observe that intervention properties of eave tubes rather than health system access to treatment are larger drivers of impact in indoor biting settings, as mosquitoes in those 	S6.2 and Figure 2


settings will be more likely to contact the eave tube.	
Optimal intervention profiles	
- Increasing deployment frequency from once to twice	S7.5-S7.6
per year for attractive targeted sugar baits, resulted in a	S8.4-S8.55
significant increase in intervention impact and less	
requirements in terms of coverage and half-life	and
- Increasing efficacy of attractive targeted sugar baits	Figure 3
did not have a significant impact	

1389

1390 **Table S5.1.**

1391 Key findings guiding target product profiles of new malaria interventions.

A summary of key results concerning impact determinants and minimal intervention profiles aswell as references to the corresponding illustrative figures is provided.



6 Results: Key determinants of impact 1396


1397 1398 Figure S6.1.

Key drivers of impact for therapeutic malaria interventions across different transmission 1399 settings. 1400

Results of sensitivity analysis identifying the determinants of intervention impact on $PfPR_{0.99}$ 1401 reduction for anti-infective monoclonal antibodies (A, B), anti-infective vaccines (C, D) and 1402 transmission-blocking vaccines (E, F). The distinct colors represent proportions of the GP 1403 1404 emulator output variance (relative importance) attributable to intervention efficacy, half-life, deployment coverage, as well as health system access. Determinants of impact are shown for 1405 both immediate and late follow-up, when interventions are applied once per year for three years 1406 in different transmission settings (see full intervention specifications in the Methods section). 1407 The transmission settings are defined by two seasonal settings (seasonal and perennial) and three 1408 types of mosquito biting patterns (low, medium and high indoor biting). The mosquito biting 1409 1410 patterns had little to no effect on the results of the sensitivity analysis for these therapeutic

1411 interventions (see results for all settings for monoclonal antibodies in figures A and B).

1412 Therefore, only the results for seasonal and perennial settings with high indoor mosquito biting 1413 are displayed for the vaccine interventions.




1414

1415 Figure S6.2.

1416 Key drivers of impact for vector control malaria interventions across different

1417 **transmission settings.**

Results of sensitivity analysis identifying the determinants of intervention impact on $PfPR_{0.99}$ 1418 reduction for attractive targeted sugar baits (A, B) and eave tubes (C, D). The distinct colors 1419 represent proportions of the GP emulator output variance (relative importance) attributable to 1420 intervention efficacy, half-life, deployment coverage, as well as health system access. 1421 Determinants of impact are shown for both immediate and late follow-up, when interventions are 1422 applied once per year for three years in different transmission settings (see full intervention 1423 1424 specifications in the Methods section). The transmission settings are defined by two seasonal settings (seasonal and perennial) and three types of mosquito biting patterns (low, medium and 1425 high indoor biting). Like for the therapeutic interventions in the previous figure, we see limited 1426 1427 difference between key drivers for attractive targeted sugar baits in different biting settings as mosquitoes sugar feed before indoor or outdoor biting. In contrast, we observe that intervention 1428 properties of eave tubes rather than health system access to treatment are larger drivers of impact 1429 1430 in indoor biting settings, as mosquitoes in those settings will be more likely to contact the eave 1431 tube.



7 Results: Feasible landscapes of optimal, constrained intervention profiles


1435 Figure S7.1.

Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-1436

infective monoclonal antibody deployed once per year. 1437

1438 The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1439 by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2.10}$ settings 1440 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each 1441 intervention characteristic was minimized in turn, while keeping the other characteristics fixed 1442 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for 1443 an anti-infective monoclonal antibody delivered alone and assessing immediate (A) and late (B) 1444 1445 follow up, as well as when delivered in combination with a blood stage drug assessing immediate

1446 (C) and late (D) follow-up. The simulated case management level (E_5) for all the displayed 1447 optimization analyses was assumed 25%.



1450 Figure S7.2.


1449

1448

1451 Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-

1452 infective monoclonal antibody deployed twice per year.

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles 1453 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1454 by minimal reduction in PfPR₀₋₉₉, y axis) across different simulated true PfPR₂₋₁₀ settings 1455 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each 1456 1457 intervention characteristic was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for 1458 an anti-infective monoclonal antibody delivered alone and assessing immediate (A) and late (B) 1459 follow up, as well as when delivered in combination with a blood stage drug assessing immediate 1460 1461 (C) and late (D) follow-up. The simulated case management level (E_5) for all the displayed optimization analyses was assumed 25%. 1462




1463 Median PrPR2 1464 Figure S7.3

1465 Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-

1466 infective vaccine deployed once per year.

1467 The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1468 by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2-10}$ settings 1469 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each 1470 intervention characteristic was minimized in turn, while keeping the other characteristics fixed 1471 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for 1472 an anti-infective vaccine delivered alone and assessing immediate (A) and late (B) follow up, as 1473 well as when delivered in combination with a blood stage drug assessing immediate (C) and late 1474 1475 (**D**) follow-up. The simulated case management level (E_5) for all the displayed optimization analyses was assumed 25%. 1476




1477

Figure S7.4. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for a transmission-

1480 blocking vaccine deployed once per year.

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles 1481 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1482 by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2.10}$ settings 1483 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each 1484 intervention characteristic was minimized in turn, while keeping the other characteristics fixed 1485 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for 1486 a transmission-blocking vaccine delivered alone and assessing immediate (A) and late (B) follow 1487 up, as well as when delivered in combination with a blood stage drug assessing immediate (C) 1488 and late (D) follow-up. The simulated case management level (E_5) for all the displayed 1489 optimization analyses was assumed 25%. 1490




1491

Figure S7.5. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for attractive

1494 targeted sugar baits deployed once or twice per year.

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles 1495 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1496 by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2.10}$ settings 1497 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each 1498 intervention characteristic was minimized in turn, while keeping the other characteristics fixed 1499 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for 1500 attractive targeted sugar baits delivered alone once per year and assessing immediate (A) and late 1501 (B) follow up, as well as when delivered twice per year assessing immediate (C) and late (D) 1502 follow-up. The simulated case management level (E₅) for all the displayed optimization analyses 1503 1504 was assumed 25%.






1507 Figure S7.6.

Feasible landscapes of optimal, constrained intervention profiles (TPPs) for eave tubes deployed once per year.

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles 1510 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified 1511 by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2.10}$ settings 1512 (rounded values, x axis) with seasonal or perennial transmission and high indoor mosquito biting 1513 (results for other biting patterns not shown as they are similar). Each intervention characteristic 1514 was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for 1515 each optimization are specified in Table S2.2). Results are shown for eave tubes delivered alone 1516 and assessing immediate (A) and late (B) follow up. The simulated case management level (E_5) 1517 for all the displayed optimization analyses was assumed 25%. 1518

1519



8 Results: Optimal intervention profiles 1520

Figure S8.1


1521

1523

Optimal intervention profiles (TPPs) for anti-infective monoclonal antibodies under 1524

various deployment regimes to achieve a *Pf*PR₀₋₉₉ reduction of at least 70%. 1525

Each figure displays minimum, constrained intervention characteristic profiles (minimum 1526 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 1527 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal 1528 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in 1529 1530 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown when assessing $PfPR_{0.99}$ reduction at immediate 1531 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the 1532 displayed optimization analyses was assumed 25%. 1533 1534




1536 Figure S8.2

1535

1537 Optimal intervention profiles (TPPs) for anti-infective vaccines under various deployment 1538 regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.

Each figure displays minimum, constrained intervention characteristic profiles (minimum 1539 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 1540 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal 1541 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in 1542 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization 1543 are specified in Table S2.2). Results are shown when assessing $P_f PR_{0.99}$ reduction at immediate 1544 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the 1545 displayed optimization analyses was assumed 25%. 1546 1547




1549 Figure S8.3

1548

1550 Optimal intervention profiles (TPPs) for transmission-blocking vaccines under various 1551 deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.

Each figure displays minimum, constrained intervention characteristic profiles (minimum 1552 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 1553 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal 1554 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in 1555 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization 1556 are specified in Table S2.2). Results are shown when assessing $P_{f}PR_{0.99}$ reduction at immediate 1557 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the 1558 displayed optimization analyses was assumed 25%. 1559 1560




1563 **Figure S8.4**

1562

Optimal intervention profiles (TPPs) for attractive targeted sugar baits under various deployment regimes to achieve a *Pf*PR_{0.99} reduction of at least 70%.

Each figure displays minimum, constrained intervention characteristic profiles (minimum 1566 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 1567 70% across different simulated true $P_f PR_{2-10}$ settings (rounded values, x axis) with seasonal 1568 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in 1569 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization 1570 are specified in Table S2.2). Results are shown when assessing $P_{f}PR_{0.99}$ reduction at immediate 1571 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the 1572 displayed optimization analyses was assumed 25%. 1573



1577 Figure S8.5

Optimal intervention profiles (TPPs) for eave tubes to achieve a *Pf*PR₀₋₉₉ reduction of at least 70%.

Each figure displays minimum, constrained intervention characteristic profiles (minimum 1580 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 1581 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal 1582 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in 1583 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization 1584 are specified in Table S2.2). Results are shown when assessing $P_{f}PR_{0.99}$ reduction at immediate 1585 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the 1586 displayed optimization analyses was assumed 25%. 1587 1588

1576